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PLASMA BIOMARKERS FOR
AGE-RELATED MACULAR DEGENERATION
JIAQIAN NI

ABSTRACT
The goal of this thesis research was to develop methods to predict susceptibility to
age-related macular degeneration (AMD). Age-related macular degeneration (AMD) is
the most common cause of legal blindness in the elderly in developed countries, and
early identification of susceptibility is important for preventing this progressive disease.
New and original evidence was found supporting the prognostic potential of plasma
advanced glycation endproducts (AGEs) as possible biomarkers for AMD, specifically
the oxidative protein modifications Nε-(carboxymethyl)lysine (CML) and pentosidine.
Quantitative analyses of plasma from AMD (n = 60) and normal control (n = 30) donors
showed that mean CML and pentosidine levels were elevated in AMD plasma by ~ 60%
and ~ 80%, respectively, while furosine was largely unchanged. Another type of
oxidative modification, carboxyethylpyrrole (CEP) adducts, were found to be ~ 2-fold
higher in AMD (n = 56) than in controls (n = 30), consistent with previous findings. Cstatistics were determined from receiver operating characteristic curves that indicate for
these plasma samples, CML discriminated between AMD and control donors with ~ 80%
accuracy, CEP adducts with ~ 81% and pentosidine with ~ 92% accuracy. In
combination with CEP, CML provided ~ 89% accuracy and pentosidine provided ~ 95%
discrimination accuracy. Overall, these results provided evidence that CML and
pentosidine are both elevated in AMD plasma and may prove useful for predicting AMD
susceptibility and for monitoring AMD therapeutics, especially in combination with CEP
biomarkers.
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CHAPTER I
INTRODUCTION

1.1 The Human Eye
The eye is a highly specialized organ of photoreception (Figure 1.1). The
process of vision formation is initiated when light energy from the environment
produces changes in specialized nerve cells in the retina, the rods and cones.
These changes result in nerve action potentials, which are subsequently relayed
to the optic nerve and then to the brain, where the information is processed and
consciously appreciated as vision. All the other structures in the eye are
secondary to this basic physiologic process, although they may be part of the
system necessary for focusing and transmitting the light to the retina, for example
the cornea, lens and iris, or they may be necessary for nourishing and supporting
the tissues of the eye, for example the choroid, aqueous outflow system, and
lacrimal apparatus.

1

Figure 1.1. Schematic Diagram of The Human Eye.
(1) Iris, the colored part of the eye that regulates the amount of light entering
the eye; (2) Cornea, the clear outer part of the eye’s focusing system located
at the front of the eye; (3) Pupil, the opening at the center of the iris, its size is
adjusted by the iris to control the amount of light that can enter the eye; (4)
Lens, a clear part of the eye behind the iris that helps to focus light, or an
image, on the retina; (5) Vitreous gel, a clear gel that fills the inside of the eye;
(6) Optic nerve, a bundle of more than one million nerve fibers that carries
visual messages from the retina to the brain; (7) Macula, the small sensitive
area of the retina that gives central vision. It is located in the center of the
retina and contains the fovea; (8) Fovea, the center of the macula and gives
the sharpest vision; (9) Retina, the light-sensitive tissue lining at the back of
the eye, which can convert light into electrical impulses that are sent to the
brain through the optic nerve. The figure and information are provided by the
National Eye Institute (NEI).
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1.2 Retina
The retina is a multi-layered sensory tissue that is bound externally by
Bruch’s membrane and on its internal aspect by the vitreous at the back of the
eye. It contains millions of photoreceptors that capture light and convert photons
into electrical impulses. These impulses travel along the optic nerve to the brain
where they are converted into images. The retina consists of two primary layers:
an inner neurosensory retina and an outer epithelium, the retinal pigment
epithelium (RPE). Between the neurosensory retina and RPE is a potential space,
the subretinal space, across which the two layers must adhere (Forrester et al.,
1996).

1.2.1 The Retina
The neurosensory retina is a thin transparent layer of neural tissue
composed of inner and outer layers and several different cell types (Figure 1.2).
The outer neurosensory retina is composed of photoreceptor cells (i.e. rods and
cones). The inner neurosensory retina is composed of other cell types, including
Müller cells, ganglion cells, bipolar cells, horizontal cells, amacrine cells and
other non-neuronal cells. Photoreceptor cells, ganglion cells and bipolar cells are
the three principle neuronal cell types for signal relay. Horizontal cells, amacrine
cells and other non-neuronal cells modulate the activity of the principle neuronal
cells.
Retinal cells are arranged in a highly organized manner, and in histological
sections appear as ten distinct layers shown in Figure 1.2. The first layer, the
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inner limiting membrane (ILM), a boundary between the vitreous humor in the
posterior chamber and the retina itself, is formed by astrocytes and the end feet
of the Müller cells. The nerve fiber layer (NFL) is formed by the expansion of the
fibers of the optic nerve. The ganglion cell layer (GCL) contains the cell bodies
and axons of ganglion cells. The synaptic junctions of bipolar, amacrine and
ganglion cells form the inner plexiform layer (IPL). Primates possess a thinner
IPL than non-primates. The thicker IPL indicates that these retinas perform more
peripheral and different image processing than in primates. The inner nuclear
layer (INL) contains nuclear bodies of bipolar cell, horizontal, and amacrine cell
bodies. The outer plexiform layer (OPL) contains the synaptic junctions of bipolar
cells and horizontal cells. The nuclei of photoreceptor cells, rod and cone cells,
form the outer nuclear layer (ONL). The outer limiting membrane (OLM) is the
layer that separates the inner segment portions of the photoreceptors from their
cell nuclei and a network where Müller cells contact the photoreceptor cell nuclei.
The photoreceptor outer segments (POS) with the rod and cone cells extend
beyond the ONL to the retinal pigment epithelium (RPE) (Forrester et al., 1996).
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Figure 1.2. Structure Arrangement of Retina. (A) Methylene blue stained
semi-thin section of guinea pig retina showing the structural arrangement of
neuronal and plexiform layers. (B) Schematic diagram of retinal connections,
including ten layers (from inner to outer): (1) ILM, inner limiting membrane; (2)
NFL, nerve fiber layer; (3) GCL, ganglion cell layer; (4) IPL, inner plexiform
layer; (5) INL, inner nuclear layer; (6) OPL, outer plexiform layer; (7) ONL,
outer nuclear layer; (8) OLM, outer limiting membrane; (9) POS, photoreceptor
outer segments; (10) RPE, retinal pigment epithelium. Six major cell types:
photoreceptor cell (cone and rod); GC, ganglion cell; AC, amacrine cell; BC,
bipolar cell; HC, horizontal cell; MC, Müller cell. Figure is obtained form
http://www.anatomy.unimelb.edu.au/researchlabs/rees/projects.html.
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1.2.2 Structure and Function of Photoreceptor Cells
Photoreceptor cells are specialized types of neurons found in the retina
that initiate phototransduction by converting light (electromagnetic radiation) into
a chain of biological processes. More specifically, the photoreceptor absorbs
photons, and through specific and complex biochemical pathways, initiates
electrochemical signals through changes in its membrane potential.
Three types of photoreceptor cells are found in vertebrate retina. The two
classic photoreceptors are rods and cones (Figure 1.3), each contributing
information used by the visual system to form a representation of the visual world,
sight. They are situated in the outer retina. The novel third photoreceptor is a
recently discovered class of photosensitive ganglion cells. These cells, found in
the inner retina, have dendrites and long axons projecting to the pretectum
(midbrain). Unlike other retinal ganglion cells, these photosensitive ganglion cells
are intrinsically photosensitive, which means that they can be excited by light
even when all influences from classical photoreceptors (rods and cones) are
blocked (Forrester et al., 1996).
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Figure 1.3. Schematic Diagram of Two Primary Types of Photoreceptor
Cells. Rod (left) and cone (right) photoreceptors have the same basic
structure. The cells are divided into two sections. The bottom portion is called
the inner segment. It contains the nucleus and the synaptic ending. The
synaptic ending attaches to the neurons which produce signals that go to the
brain. The top portion is called the outer segment. The outer segment is
comprised of a membrane which is folded into several layers of disks. The
disks are comprised of cells that contain the molecules that absorb the light
(Reproduced from Young et al., 1970).
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Light initiates the phototransduction cascade and the retinoid visual cycle
by isomerization of 11-cis-retinaldehyde bound to the visual pigment proteins in
the rod and cone photoreceptor cells. Each photoreceptor cell is composed of an
outer and inner segment. The outer segment contains the visual pigments and is
in contact with the RPE cells. In contrast, the inner segment is important for cell
metabolism and synapse with the bipolar and horizontal cells in the retina. The
bipolar cells are vertically oriented and synapse between the photoreceptor cells
and the ganglion and amacrine cells. The axons of the ganglion cells form the
retinal unmyelinated nerve fiber layer and eventually the axons of the optic nerve.
The horizontal and amacrine cells contain short axons and function to modulate
and transform visual information at short distances. The main glial cell of the
retina is the Müller cell, which provides structural support and nutrition for the
retina and is thought to participate in the regeneration of cone visual pigments
(cone visual cycle). The vascular supply for the inner retina is from the central
retinal artery and for the outer retina from the choroidal circulation.
There are approximately 115 million rods and 6.5 million cones in the
human eye. Rods are responsible for sensing contrast, brightness, and motion,
while cones subserve fine resolution, spatial resolution, and color vision. The
density of rods and cones varies in different regions of the retina, the periphery
being rod-dominated (30,000 per mm2) while cone density increases nearer the
macula (150,000 per mm2 at the fovea), the fovea being exclusively cones
(Forrester et al., 1996).
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1.2.3 Retinal Pigment Epithelium (RPE)
The RPE is a continuous monolayer of pigmented epithelial cells between
the neural retina and Bruch’s membrane. RPE cells vary in size and shape
depending on age and location. The basal membrane of RPE cells is in contact
with Bruch’s membrane, a multilayered extracellular matrix that separates the
RPE from the underlying choriocapillaris. The apical side of the RPE associates
with the tips of the outer segments of photoreceptor cells. RPE cells form a highly
organized hexagonal pattern of cells (Figure 1.4) with the number of cells varying
from 4.2 to 6.1 million (Forrester et al., 1996).
The RPE has many physical, optical, metabolic/biochemical and transport
functions and plays a critical role in normal visual processes (Figure 1.4). The
pigmented cells in the RPE absorb scattered light (Bok et al., 1993; Boulton et al.,
2001a) and support the survival and normal functioning of photoreceptors by
acting as the outer blood-retinal barrier to control exchange between the
underlying choroidal blood vessels and overlying photoreceptors (Ban et al.,
2000; McBee et al., 2001). The RPE transports ions, water, and metabolic end
products from the subretinal space to the blood (Miller et al., 1990; Dornonville et
al., 1993; Marmor et al., 1999; Hamann et al., 2000). It also takes up nutrients
such as glucose, retinol, and fatty acids from the blood and delivers these
nutrients to photoreceptors.
Importantly, retinoid is constantly exchanged between photoreceptors and
the RPE (Baehr et al., 2003; Besch et al., 2003; Thompson et al., 2003) because
the photoreceptors are unable to isomerize all-trans-retinaldehyde, formed after
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photon absorption and isomerization of 11-cis-retinaldehyde. The RPE
enzymatically converts all-trans-retinaldehyde to 11-cis-retinaldehyde, a process
known as the rod visual cycle. The voltage-dependent ion conductance of the
apical membrane enables the RPE to stabilize the ion composition in the
subretinal space, which is essential for the maintenance of photoreceptor
excitability (Steinberg et al., 1983; Steinberg et al., 1985). Another RPE function
in the maintenance of photoreceptor health is the phagocytosis of photoreceptor
outer segments (Bok et al., 1993; Strauss et al., 1998; Gal et al., 2000;
Finnemann et al., 2003). The shed photoreceptor outer segments are digested in
the RPE, and essential substances such as retinaldehyde are recycled and
returned to the photoreceptors to rebuild light-sensitive outer segments. In
addition, the RPE is able to secrete a variety of growth factors that help maintain
the structural integrity of the choriocapillaris endothelium and photoreceptors
(Strauss et al., 2005). Furthermore, the secretory activity of the RPE plays an
important role in establishing the immune privilege of the eye by secreting
immunosuppressive factors (Streilein et al., 2002; Ishida et al., 2003). With these
complex, different functions, the RPE is essential for visual function. A failure of
any one of these functions can lead to degeneration of the retina, loss of visual
function, and blindness.
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Figure 1.4. Summary of Retinal Pigment Epithelium (RPE) Functions. The
RPE is a monolayer of pigmented cells forming a part of the blood/retina
barrier. It plays an important role in the normal visual process with the function
of

light

absorption,

protection

against

photo-oxidation,

transepithelial

transportation of nutrients and ions, spatial buffering of ions in the subretinal
space, photoreceptor outer segment phagocytosis and secretion. (Reproduced
from Strauss et al., 2005).

1.3 Age-related Macular Degeneration (AMD)
Age-related

macular

degeneration

(AMD)

is

a

progressive

neurodegenerative disease of the central retina, and represents the most
common cause of legal blindness in industrialized countries (Klaver et al., 1998).
It is a leading cause of vision loss in Americans 60 years of age and older. About
9 million individuals in the United States have AMD, and about 3 million
Americans are at high risk of developing AMD (Friedman et al., 2004). Agerelated macular degeneration (AMD) gradually destroys sharp, central vision,
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because of the degradation of macula (Figure 1.5), the central part of the retina
that provides high acuity vision (Bird et al., 1995; de Jong et al., 2006).

1.3.1 Classification
Based on criteria proposed by the Age-Related Eye Disease Study
(AREDS) (Age-Related Eye Disease Study Group, 2000; Jager et al., 2008), the
stages of AMD disease progression are categorized by the size and extent of
drusen (deposition of extracellular debris on Bruch’s membrane), the
manifestations of geographic atrophy and neovascular changes (Figure 1.6).
Early AMD (AREDS category 2) is characterized by the presence of less than 20
medium size drusen or retinal pigmentary abnormalities (Figure 1.6A). At this
stage, blurred vision and abnormal dark adaptation may occur, but the visual loss
is generally mild and the visual symptom is inconspicuous. Intermediate AMD
(AREDS category 3) is characterized by at least one large drusen, numerous
medium size drusen, or geographic atrophy (GA) that does not extend to the
center of the macula (Figure 1.6B). Advanced AMD (AREDS category 4) include
non-neovascular advanced dry AMD (geographic atrophy) and neovascular or
wet AMD.
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Figure 1.5. Normal Fundus. The area within the outer white circle (indicating
a retinal diameter of about 6 mm) is the macula. The inner circle (diameter, 0.8
mm) borders the fovea, which is the center of the macula, where the
preponderance of cones over rods is highest for sharp vision. The retina is the
inner lining at the back of the eyeball. The enlarged part shows the two outer
layers that contain the purple light-sensitive rod and cone photoreceptor cells
supported by Müller cells, all embedded in the inter-photoreceptor matrix, in
close contact with the RPE. The RPE is surrounded by two extracellular
matrixes, the inter-photoreceptor matrix and Bruch’s membrane. Between the
RPE and the outer wall of the eye (sclera) are Bruch’s membrane, the
choriocapillaris, and a larger vessel layer, the choroid. (Reproduced from de
Jong et al., 2006).
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Figure 1.6. Classification of AMD. Column A indicates early AMD in two
maculas: the macula shown on the left side contains small drusen (arrow) and
some large, indistinctly bordered drusen in the fovea; the macula shown on
the right side contains more drusen and focal hyperpigmentation (arrow);
column B shows intermediate AMD with crystalline and calcified drusen
(arrows on the left); on the right side are large confluent drusen leading to a
drusenoid detachment of the RPE, with hyperpigmentation (arrows); column C
shows advanced dry AMD (geographic atrophy), with a central island in which
photoreceptors are still functioning (arrow); column D shows wet AMD
(choroidal neovascularization) with a subfoveal hemorrhage surrounded by
detachment of the RPE (arrows) (Reproduced from de Jong et al., 2006).
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Advanced dry AMD or geographic atrophy (Figure 1.6C) is characterized
by the regional loss of photoreceptor and RPE cells in the macula, gradually
blurring central vision in the affected eye. Advanced neovascular AMD (wet
AMD), also known as choroidal neovascularization (CNV) (Figure 1.6D) occurs
when blood vessels in the choroid abnormally grow through Bruch’s membrane
into the retina. These new blood vessels tend to be very fragile and often leak
blood and fluid, and can rupture, rapidly causing irreversible damage to the
macula. Although wet AMD represents less than 15% of AMD prevalence, it is
responsible for more than 80% of the debilitating visual loss in AMD (Friedman et
al., 2004).

1.3.2 Risk Factors
Demographic factors. The greatest risk factor for AMD is age. Age reflects the
level of free radical oxidative damage accumulated in the body (Jager et al.,
2008). Although AMD may occur during middle age, studies show that people
over age 60 are clearly at greater risk than younger age groups. The incidence,
prevalence, and progression of all forms of AMD increases with advancing age
(Smith et al., 2001; Klein et al., 2002; Mitchell et al., 2002a).
Epidemiological studies show significant variation in the prevalence of
advanced AMD among different racial/ethnic groups. All forms of AMD are more
prevalent in the white population than more darkly pigmented races (Pieramici et
al., 1994; Friedman et al., 1999; Klein et al., 2003), which suggests that melanin
may be protective in darkly pigmental races. The presence of melanin also
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seems to protect against formation of RPE lipofuscin, a marker of cellular
senescence and promoter of oxidative damage (Kayatz et al., 2001; Sundelin et
al., 2001).

Genetic factors. Genetic background influences susceptibility to AMD. Much
evidence points to a familial component of AMD, including twin-concordance,
linkage studies, and biomolecular investigations (Meyers et al., 1994). Recently,
common genetic polymorphisms in different complement genes have been
reported to increase risk or confer protection for AMD. Genetic variants of the
CFH (complement factor H), ARMS2 (age-related maculopathy susceptibility 2,
also known as LOC387715), HTRA1 (high temperature requirement factor A1),
C3 (complement 3) and CFHR5 (complement factor H related 5) genes have
been shown to be associated with an increase risk for AMD in Caucassian
populations (Edwards et al., 2005; Hageman et al., 2005; Haines et al., 2005;
Klein et al., 2005; Rivera et al., 2005; Gold et al., 2006; Hageman et al., 2006;
Yates et al., 2007). In particular, the CFH His402 variant, located in the short
consensus repeat 7 (SCR7) of factor H, has consistently been shown to be
associated with increased risk to AMD in numerous studies (Hageman et al.,
2005; Scholl et al., 2007).

Smoking. Cigarette smoking is a significant risk factor for AMD. Smoking has
been associated with an increased risk of developing AMD in most population
based studies (Delcourt et al., 1998; Klein et al., 1998). Both prior and current
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smokers are at increased risk for AMD (Hyman et al., 1983; Smith et al., 1996),
and these individuals tend to develop AMD 5 to 10 years before non-smokers,
respectively (Mitchell et al., 2002b). This may be due to smoking’s effect on
antioxidant metabolism and choroidal blood flow.

1.3.3 AMD Disease Mechanisms
Although genetic and environmental factors contribute to age-related
macular degeneration (AMD), specific mechanisms of disease onset and
progression remain unclear. Current pathophysiologic concepts suggest that
AMD is a multi-factorial disease, that affects initially the RPE and the thin
connective tissue layer (Bruch’s membrane) interposed between the RPE and
choriocapillaris (Jager et al., 2008). Electron microscopy reveals accumulation of
lipofuscin granules in the cytoplasm of RPE, and the deposition of randomly
distributed amorphous or granular material (drusen) in Bruch’s membrane
(Feeney et al., 1985). Histochemically, lipofuscin appears to contain mainly
extracellular matrix-associated lipids and glycoproteins (Hageman et al., 1999).
However, recent proteomic analyses of RPE lipofuscin show that the granules
contain very little protein but do exhibit oxidative protein metabolism (Ng et al.,
2008). The apparent impairment of metabolic

exchange between the

choriocapillaris and the RPE leads to secondary degeneration of photo-receptor
cells, which subsequently results in further deposition of abnormal metabolites on
the Bruch’s membrane, and finally, induces the permanent loss of the visual
functions in the affected macular area (Bird et al., 1992; Starita et al., 1997).
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Biochemical studies suggest that increasing lipid deposits in Burch’s membrane
exponentially correlate with age, with the macular area preferentially affected
(Holz et al., 1994).

1.3.4 Treatment
Choroidal neovascularization (CNV), the wet form of advanced AMD, is
responsible for more than 80% of legal blindness caused by AMD. Wet AMD can
be treated most effectively with ocular injections of anti-VEGF (vascular
endothelial growth factor). Abnormally high levels of VEGF occur in eyes with wet
AMD and promote the growth of new blood vessels. Treatment with anti-VEGF
blocks the effects of VEGF. It can help slow down vision loss from AMD and in
some cases improve sight (Gragoudas et al., 2004; Rosenfeld et al., 2006).
However, there is still no effective treatment for dry AMD.
Laser surgery has been used to destroy fragile, leaky blood vessels,
however, laser treatment may also destroy surrounding healthy tissue and vision.
Only a small percentage of people with wet AMD can be treated with laser
surgery. The risk of new blood vessels developing after laser treatment is high
and vision loss often progresses despite repeated treatments (Jager et al., 2008).
Photodynamic therapy has also been used to treat wet AMD. A
photosensitizing drug such as verteporfin is injected in the blood stream, then, is
activated by a 689 nm laser focused on the macula. The activated drug destroys
the new blood vessels and slows the rate of vision decline, but treatment results
often are temporary (Jager et al., 2008).
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1.4 Oxidative Stress
Molecular dioxygen, O2, is essential for cellular respiration in all aerobic
organisms. Oxygen is used in mitochondria to help generate adenosine
triphosphate (ATP) during oxidative phosphorylation. However, oxidative stress
has been implicated in variety of disease processes, especially age-related
disorder, including the cardiovascular disease (Damy et al., 2004; Dalle et al.,
2006), eye diseases like age-related macular degeneration (Beatty et al., 2000;
Crabb et al., 2002; Gu et al., 2003; Zarbin et al., 2004; Ebrahem et al., 2006;
Shen et al., 2007; Trieschmann et al., 2007; Hollyfield et al., 2008).

1.4.1 Chemistry of Oxidative Stress
Oxidative stress is caused by an imbalance between the production of
reactive oxygen and a biological system’s ability to readily detoxify the reactive
intermediates or easily repair the resulting damage. The particularly destructive
aspect of oxidative stress is the production of reactive oxygen species (ROS),
which include free radicals (such as superoxide and hydroxyl ion), hydrogen
peroxide, and singlet oxygen (Figure 1.7) (Winkler et al., 1999). These ROS are
often the byproducts of oxygen metabolism. The main sources of intracellular
ROS generation are the mitochondrial and microsomal electron transport chains
and NAD(P)H oxidases. These ROS are highly reactive due to the presence of
unpaired valance shell electrons. ROS form as a natural byproduct of the normal
metabolism of oxygen and have important roles in cell signaling. However, during
times of environmental stress, ROS levels can increase dramatically, which can
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result in significant damage to cell structure. This oxidative damage initiated by
ROS is a major contributor to the functional decline that is characteristic of aging.

Superoxide anion
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Figure 1.7. Generation of Reactive Oxygen Radicals. Oxygen accepts an
electron to form the superoxide anion, which in turn can accept another
electron and react with protons to form hydrogen peroxide. The hydrogen
peroxide is easily degraded to hydroxyl radical, which is very reactive and
subsequently is neutralized by accepting a proton. Singlet oxygen is
generated when a chromophore absorbs energy and transforms the energy
to molecular oxygen (Reproduced from Winkler et al., 1999).

1.4.2 Oxidative Stress in the Retina
The retina is particularly susceptible to oxidative stress because of its high
consumption of oxygen, its high proportion of polyunsaturated fatty acids (PUFA)
(Beatty et al., 2000), and its exposure to visible light. The RPE also generates
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ROS from phagocytosis (Miceli et al., 1994) of the photoreceptor outer segments
(POS) that contain high concentrations of radicals, photo-damaged proteins and
oxidized lipids. Some of these oxidative-damaged proteins and lipids are not
completely digested by RPE lysosomes and accumulate within RPE cells and
become a major source of photosensitizer lipofuscin during RPE aging (Kennedy
et al., 1995).
In healthy retina, the RPE can defend against oxidative stress by (1)
absorbing and filtering light, (2) detoxifying ROS by enzymatic and nonenzymatic antioxidants, and (3) self-repairing damaged macromolecules. Various
pigments in RPE and photoreceptor cells are able to absorb light of different
wavelengths (Landrum et al., 1999; Beatty et al., 2001). Blue light is most
dangerous for RPE, since it triggers photo-oxidation of lipofuscin and other
components to generate toxic substances (Rozanowska et al., 1995; Sparrow et
al., 2000). High amounts of catalase (Miceli et al., 1994; Tate et al., 1995),
superoxide dismutase (Oliver et al., 1992; Frank et al., 1999), and glutathione as
well as carotenoids (Newsome et al., 1994; Beatty et al., 2000) help detoxify and
remove ROS once they are generated in RPE cells.

1.4.3 Oxidative Stress and AMD
Oxidative stress may play a major role in the etiology and pathogenesis of
AMD. Vision loss in AMD results from photoreceptor and RPE damage in the
central retina and the initial pathogenesis appears to involve degeneration of
RPE cells (Green et al., 1985; Spraul et al., 1996; Zarbin et al., 1998). Because
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of the close interaction between RPE and photoreceptors in both nutritional and
metabolic aspects (Marmorstein et al., 1998), progressive RPE dysfunction is
thought to cause a secondary degeneration of rods and cones. The pathological
changes leading to the loss and/or dysfunction of macular RPE cells is thought to
involve oxidative stress and to be central to the etiology of this disease.
Lifelong chronic cumulative oxidative stress constitutes a significant risk
factor for AMD because the retinal environment favors the generation of ROS
(van der Hagen et al., 1993; Snodderly et al., 1995; Rose et al., 1998; Winkler et
al., 1999). Evidence from a variety of studies suggests that RPE cells are
susceptible to oxidative damage (Liang et al., 2003). Thus, it is of considerable
interest to understand factors that modulate RPE cell function and viability in an
oxidative stress environment. Elucidating the mechanism responsible for RPE
oxidative injury could provide the basis for designing new strategies to treat or
prevent AMD disease.
The relationship between oxidative stress and AMD is supported by
epidemiologic evidence pointing toward multiple oxidative process-related factors.
These factors include age, environmental inducers such as cigarette smoking
(Chan et al., 1998; Schmidt et al., 2005), intense sunlight exposure
(Cruickshanks et al., 1993), and antioxidant status, all of which can possibly
enhance ROS generation and increase the risk for RPE degeneration. Previous
studies reveal that heavy cigarette smokers have a 2.4 times higher risk of AMD
(Seddon et al., 1996; Chan et al., 1998).
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Antioxidant carotenoids and vitamins have been hypothesized to play a
protective role against oxidation.

Lutein and zeaxanthin exist in high

concentrations in the macula and are entirely of dietary origin. The antioxidant
properties of the carotenoids include the ability to quench free radical reactions
and therefore prevent lipid peroxidation and protect against photochemical
reactions (Krinsky et al., 1982; Packer et al., 1993). Vitamin C, the most effective
aqueous phase antioxidant in serum (Frei et al., 1989), and vitamin E, the major
chain-breaking antioxidant of cellular membranes (Packer et al., 1990) are two
other antioxidants essential for protection against disease progression and
degenerative disorders caused by oxidative stress.

The Eye Disease Case

Control (EDCC) study reported that high dietary and serum levels of carotenoids
and a high antioxidant index (a composite score based on serum carotenoids,
selenium, vitamin C and E) was significantly associated with reduced risk of AMD
progression (EDCC Study Group, 1993). Several other case control and
population based studies have demonstrated inconsistent results. However, the
overall evidence suggests the existence of an important association between
antioxidants and AMD, especially considering potentially modifiable risk factors
like smoking.

1.4.4 Carboxyethylpyrrole Biomarkers of AMD
Carboxyethylpyrrole (CEP) modifications are generated by covalent
adduction of primary amino groups (e.g., protein ε-lysyl NH2) with 4-hydroxy-7oxohept-5-enoic acid, an oxidation fragment derived uniquely from DHA-
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containing phospholipids (Gu et al., 2003). DHA is the most oxidizable of all fatty
acids and although rare, its highest abundancy in human tissues is found in
retinal photoreceptor outer segments (Fliesler et al., 1983). The high oxygen
tension in the retina coupled with light provides a permissive environment for the
generation of oxidative post-translational modifications. For example, rodents
exposed to intense light accumulate elevated CEP adducts in the retina and
elevated CEP adducts and autoantibodies in plasma (Gu et al., 2004;
Renganathan et al., 2003).

Why ocular tissues in AMD patients are more

susceptible to oxidative damage than normal eye tissue remains to be
determined but oxidative markers formed from retina-rich components like DHAlipids offer a potential early warning system for predicting AMD susceptibility.
CEP protein adducts belong to a family of 2-(ω-caroxyalkyl)pyrrole adducts
generated from the oxidation of polyunsaturated fatty acids (PUFAs) (Figure 1.8)
(Gu et al., 2003).

Oxidative fragmentation of linoleic and arachidonic acid

produces oxidation products that react with proteins to generate 2-(ωcaroxyheptyl)pyrrole (CHP) and 2-(ω-caroxypropyl)pyrrole (CPP) adducts,
respectively (Kaur et al., 1997). The CHP and CPP adducts were detected in
oxidized low density lipoprotein and human plasma (Kaur et al., 1997). The
phosphatidylcholine (PC) esters of these PUFA oxidation products are also
biologically active products of oxidized low density lipoprotein oxidation (oxLDL).
They are found in atherosclerotic plaques and oxLDL (Podrez et al., 2002;
Subbanagounder et al., 2002; Sun et al., 2002). The detection of CPP or CHP
does not uniquely indicate the oxidative damage of linoleic or arachidonic acid
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because these protein adducts can also arise from other common PUFAs. In
contrast, only docosahexaenoic acid (DHA) gives rise to 2-(ω-caroxyethyl)pyrrole
(CEP) adducts, by oxidative cleavage to 4-hydroxy-7-oxohept-5-enoic acid and
reaction of the latter with proteins.

Figure 1.8. Generation of Carboxyethylpyrrole Adducts.

Oxidative

fragmentation of polyunsaturated fatty acids generates a host of oxidation
products, including the hydroxy-ω-oxoalkenoic acids HODA, HOOA and
HOHA which give rise to a host of protein modifications, including the family of
carboxyalkylpyrrole protein adducts CHP, CPP and CEP. HODA, 9-hydroxy12-oxodec-10-enoic acid; HOOA, 5-hydroxy-8-oxooct-6-enoic acid; HOHA, 4hydroxy-7-oxohept-5-enoic acid; CHP, 2-(ω-carboxyheptyl)pyrrole; CPP, 2-(ωcarboxypropyl)pyrrole; CEP, 2-(ω-carboxyethyl)pyrrole (Reproduced from Gu
et al., 2003).
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1.5 Advanced Glycation End-Products
1.5.1 Glycated Modification of Proteins
Extracellular and cellular proteins can be modified by the Maillard reaction
(Maillard et al., 1912; Glomb et al., 2001), which involves glycation, or nonenzymatic glycosylation. The aldehyde groups of glucose and other reducing
sugars can react reversibly with primary amino groups of proteins to form Schiff
bases and Amadori adducts (Figure 1.9). Overtime, the initial glycation products
may undergo subsequent intramolecular rearrangements and oxidation reactions
(glycoxidation) and ultimately transform into stable, irreversibly bound advanced
glycation end-products (AGEs) (Ahmed et al., 1997) (Figure 1.10). The amino
groups of the side chains of arginine and lysine are the primary targets for this
type of posttranslational oxidative modification. AGEs appear to play an
important role in age-related pathologies.
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Figure 1.9. Non-Enzymatic Glycation, the Maillard Reaction. The primary
amine group (nucleophilic) of an amino acid reacts with the reactive carbonyl
group of a reducing sugar to produce N-substituted glycosylamine (Schiff
base). The unstable glycosylamine undergoes Amadori rearrangement,
transforming into more stable aldoamines (Amadori products). Following a
chain of not well-understood chemical rearrangements, the Amadori products
are irreversibly bound to the target molecules and finally form the advanced
glycation end-products (AGEs) (Reproduced from Niwa et al., 2006).

Figure 1.10. Pathways for the Formation of AGEs (Reproduced from
Thornalley et al., 2003).
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1.5.2 Molecular Structures and Formation of Several AGEs
Recent investigations have revealed that AGEs may play a role in aging
changes (Sell et al., 1990; Brownlee et al., 1995) and neovascularization
(Yamagishi et al., 1997; Lu et al., 1998). They accumulate especially, but not
exclusively, on long-lived structural proteins, such as collagens and lens
crystallins, and are recognized as important instigators of age-related pathology
by altering macromolecular structure and function (Monnier et al., 1992).
Although these reactions occur during our entire life span, there is evidence that
they are enhanced in pathogenic aging, leading to increased tissue levels of AGE
adducts, such as Nε-(carboxymethyl)lysine (CML) (Shaw et al., 2002),
pentosidine, and argpyrimidine (Figure 1.11A) (Thornalley et al., 1999; Wilker et
al., 2001; Thorpe et al., 2003). Formation of AGEs is accelerated by oxidative
stress (Singh et al., 2001).
Nε-(carboxylmethyl)lysine (CML) is a stable, nonenzymatic chemical
modifications of protein lysine residues formed by oxidative breakdown of
Amadori products (Fu et al., 1996) and during metal-catalyzed auto-oxidation of
polyunsaturated fatty acids (PUFAs) in the presence of protein (Miyata et al.,
1998; Jump et al., 2002). This major modification by the Maillard reaction
accumulates in several human tissues during aging and various diseases
including AMD (Ishibashi et al., 1998) (Figure 1.11B). Previous studies have
reported the concentration of CML in control plasma as measured by ELISA to
be 0.97 nmol/ml(Sebeková et al., 2001), 1.81 nmol/ml (Heidland et al., 2004),
2.09 nmol/ml (Krajcovicová et al., 2002).
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Pentosidine is an AGEs that crosslinks arginine and lysine residues in
proteins with carbonyl derivatives (Figure 1.11B). The plasma concentration of
pentosidine in normal controls has been reported from chromatographic analyses
to be 0.90 pmol/mg (Odetti et al., 2005), 0.94 pmol/mg (Odetti et al., 1992) and
1.27 pmol/mg (Słowik et al., 2004).
Argpyrimidine is a major arginine modification by methylglyoxal (Oya et al.,
1999). Methylglyoxal is produced from several metabolic pathways and has been
detected in serum as well as tissues (Haik et al., 1994; Chaplen et al., 1998).
Methylglyoxal is produced during the Maillard reaction with sugars such as
glucose (Thornalley et al., 1999), and reacts rapidly with proteins to produce
argpyrimidine (Phillips et al., 1993) (Figure 1.11B). Variable estimates of the
argpyrimidine concentration in normal control plasma proteins have been
reported, including 1 fmol/mg by ELISA (Raj et al., 2004), 4.4 pmol/mg by amino
acid analysis (Wilker et al., 2001) and 13.9 pmol/mg by LC-mass spectrometry
(Thornalley et al., 2003).
The fluorescence properties of pentosidine and argpyrimidine are similar
with an excitation wavelength (λex) of 335 nm and an emission wavelength (λem)
of 385 nm (Sell et al., 1989).
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Figure 1.11. (A) Molecular Structures of AGEs; (B) Multiple Pathways
Leading

to

Formation

of

CML,

Pentosidine

and

Argpyrimidine.

(Reproduced from Wilker et al., 2001; Shaw et al., 2002; Thornalley et al.,
2003).
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1.5.3 Advanced Glycation End-Products and Disease
AGEs are a complex and heterogeneous group of compounds that have
been implicated in diabetes related complications. At present it is not known if
they are the cause or the consequence of the complications. The presence of
advanced glycation end-products (AGE) is closely related to hyperglycaemia and
may be involved in diabetes related complications such as retinopathy,
neuropathy and nephropathy (Vlassara et al., 1996; Ulrich et al., 1997). Apart
from diabetic microvescular disease, AGEs have also been implicated in a wide
range of pathologies such as connective tissue diseases like rheumatoid arthritis
and neurological conditions such as Alzheimer’s disease and end-stage renal
disease (ESRD) (Bucala et al., 1992; Lee et al., 1992). Whether they are the
cause of such pathologies or merely a by-product is not known. Despite their
complexity and widespread distribution, the currently known AGEs represent the
same chemical outcome, namely, the formation of covalent protein modifications
(Bucala et al., 1997).
CML has been suggested to represent a general marker of oxidative stress
and long term damage to proteins in aging, atherosclerosis, and diabetes (Reddy
et al., 1995). Apparently glycation reactions initiate a complex series of oxidative,
cleavage, and rearrangement reactions which lead to the accumulation of AGEs
in diabetes and aging (Monnier et al., 1986; Brownlee et al., 1988; Makita et al.,
1992). Pentosidine has also been reported to increase in diabetes (McCance et
al., 1993). Plasma pentosidine has been associated with hypertension, ischemic
heart disease, and aortic calcification in diabetes (Kitauchi et al., 2004). The role
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of different types of AGE in the pathogenesis of diabetic complications is still
unclear. For example, serum levels of CML increase in diabetic patients with
retinopathy but not with nephropathy whereas the levels of pentosidine increase
in both groups (Miura et al., 2003).
Furosine (ε-N-furoylmethyl-L-lysine), a marker of early protein glycation, is
formed during acid hydrolysis of the protein-bound Amadori product fructoselysine (Figure 1.12). This amino acid has been used to measure the early stages
of Maillard reaction in biological samples. The yield of furosine is described to be
constant under controlled conditions. Published yields range from 20% to 32%
after hydrolysis in 6 M hydrochloric acid and from 29% to 46% after hydrolysis in
7.8 M hydrochloric acid (Krause et al., 2003). Literature values for the plasma
concentration of furosine in normal control from chromatographic analyses
include 0.87, 0.91 and 1.01 nmol/mg plasma protein (Friedlander et al., 1996;
Floridi et al., 1998; Riviere et al., 1998). The quantification of furosine can be
used to predict the progression of diabetic complications (Monnier et al., 2005).
Furosine was used to monitor possibly unknown diabetics in our study group.
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Figure 1.12. Chemical Pathways Leading to The Formation of Glycation
(furosine) and Glycoxidation Product (the lipoxidation/glycoxidation product
CML and pentosidine) (Reproduced from Frank et al., 2000).

1.5.4 AGEs in Age-related Macular Degeneration
Bruch’s membrane and the overlying RPE form a dynamic filtration barrier
between the dense vascular network of the choriocapillaris and the retina.
Bruch’s membrane displays structural and physiological changes with age,
including reconfiguration of chemical composition and an increase in overall
thickness (Okubo et al., 1999; Zarbin et al., 2004). AGEs accumulate during
aging and have been observed in postmortem eyes within the RPE, Bruch’s
membrane, and subcellular deposits (drusen) (Figure 1.13). Qualitatively, AGEs
are increased in RPE, drusen, and Bruch’s membrane from aging eyes and in
patients with AMD (Ishibashi et al., 1998; Handa et al., 1999; Glenn et al., 2007),
and it has been shown that these adducts also occur in basal lamina deposits
from human macula (Yamada et al., 2006). AGE formation with extracellular
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matrices has been proposed to contribute to diminished barrier and filtration
properties in Bruch’s membrane. Glycoxidation and lipoxidation reactions
induced by oxidative stress have been linked to drusen formation and are
proposed to contribute to the progression of AMD (Crabb et al., 2002). The
extracellular deposits around Bruch’s membrane instigate chronic local
inflammation, which contributes to the development of AMD (Sarks et al., 1999;
Hageman et al., 2001).
The formation of CML has been shown to occur at sites of oxidative stress
with hydroxyl radical formation (Nagai et al., 1997). CML has been detected in
soft, macular drusen (Crabb et al., 2002) and in basal laminar and basal linear
deposits (Figure 1.14) (Ishibashi et al., 1998). It has been suggested that oxidant
stress may contribute to damage to Bruch’s membrane, facilitating choroidal
neovascularization (CNV) (Ryan et al., 1994). The appearance of CML and CEP
in drusen supports the hypothesis that oxidative protein modifications have a role
in drusen formation and the pathogenesis of AMD.
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Figure 1.13. AGE-Linked Autofluorescence in Human Bruch’s Membrane
and RPE. A spectral imaging system was used to determine the presence of
AGE-linked autofluorescence in human specimens. Sections were assessed
by confocal microscopy, using a λ scan approach to identifying areas of
autofluorescence within each set wavelength. Each different band was then
pseudocolored for ease of identification, as shown in a representative sample
from an 88-year-old man with some evidence of drusen. (A) Cell nuclei stained
with DAPI (blue; arrows). (B) Localization of fluorescent AGEs within the RPE
layer and Bruch’s membrane with excitation emission spectra in a 400- to 460nm range (red; left arrowhead: AGEs at the level of Bruch’s membrane; right
arrowhead: AGEs in the RPE). The additional staining throughout the section
is indicative of additional AGE accumulation in the collagenous choroids. (C)
Autofluorescence (yellow) of lipofuscin (*) was also observed at a
characteristic wavelength within the RPE cytoplasm. (D) Composite image of
(A - C). Original magnification, x 600. (Reproduced from Glenn et al., 2009).
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Figure 1.14. Immunohistochemistry for Nε-(carboxymethyl)lysine (CML).
A: Soft, macular drusen in the eye of an 81-year-old woman (control). CML
immunoreactivity is observed in Bruch’s membrane, and accentuated in the
soft, macular drusen (arrow), and basal laminar and basal linear deposits
(arrowheads). Note the absence of CML immunoreactivity in the RPE layer
(original magnification 3100). B: A fibrous cellular choroidal neovascular
membrane surgically excised from the eye of a 70-year-old man with agerelated macular degeneration. Partially intact RPE cells show CML
accumulation (arrows) (original magnification 3100) (Reproduced from
Ishibashi et al., 1998).

The localization of pentosidine in human RPE-Bruch's membrane-choroid
complexes has been reported from immunohistochemical experiments. In an 82year-old nondiabetic eye with no known history of AMD, Bruch's membrane, the
extracellular matrix of the choroid, and choroidal vasculature showed
immunohistochemical evidence of pentosidine (Figure 1.15A). In the 82-year-old
nondiabetic eye, basal laminar deposits (BLDs) and drusen showed evidence of
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pentosidine. These structures showed prominent staining with the antipentosidine antibody (Figure 1.15A, B) compared with the control sections
(Figure 1.15C, D) (Handa et al., 1999).

Figure 1.15. Immunohistochemical Localization of Pentosidine in Human
Bruch's Membrane and Drusen. (A) In an 82-year-old nondiabetic eye
without known AMD, Bruch's membrane including BLD and choroidal
extracellular matrix and vasculature showed positive immunoreactivity. (B) A
high-power image of a drusen (DRU) shows staining for pentosidine. (C)
Minimal reaction was observed with addition of nonimmune rabbit IgG or (D)
the anti-pentosidine antibody preincubated with excess pentosidine-modified
BSA in the 82-year-old nondiabetic eye (Reproduced from Handa et al., 1999).
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1.6 Long Term Goals and Specific Aims
The long term goal of this research is to develop methods to predict AMD
susceptibility early, prior to clinical signs of the disease, essentially as serum
cholesterol measurements are used today for risk management of cardiovascular
disease. The specific aims of the thesis research are: (1) to quantify CML,
pentosidine and argpyrimidine in AMD and control plasma as potential AMD
biomarkers; and (2) to compare the discrimination accuracy of CML and
pentosidine biomarkers for AMD with that of CEP biomarkers for AMD.

38

CHAPTER II
EXPERIMENTAL METHODS

2.1 Materials
5% phenylisothiocyanate in n-heptane

Applied Biosystems (Warrington, UK)

AccQ•Tag™ Ultra borate buffer

Waters (Milford, MA)

AccQ•Tag™ Ultra Eluent A

Waters (Milford, MA)

AccQ•Tag™ Ultra Eluent B

Waters (Milford, MA)

AccQ•Tag™ Ultra Reagent

Waters (Milford, MA)

AccQ•Tag™ Ultra reagent powder

Waters (Milford, MA)

Acetone, HPLC grade

Fisher Scientific (Pittsburg, PA)

Acetonitrile, HPLC Grade

Fisher Scientific (Pittsburg, PA)

Amino Acid Standard H

Pierce (Rockford, IL)

Amino Acid Standard H

Thermo Scientific (Rockford, IL)

Ammonium Acetate, HPLC Grade

J.T. Baker (Phillipsburg, NJ)
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Butylated Hydroxytoluene (BHT)

Sigma Chemical Co. (St. Louis, MO)

Glacial Acetic Acid (AA)

Fisher Scientific (Pittsburg, PA)

Hydrochloride, Ultrapure Reagent

J.T. Baker (Phillipsburg, NJ)

Methanol, HPLC Grade

Fisher Scientific (Pittsburg, PA)

N, N-diisopropylethylamine (DIEA)

Applied Biosystems (Warrington, UK)

Nε-(carboxymethyl)lysine (CML)

NeoMPS, Inc. (San Diego, CA)

Pentosidine

IMARS (Cleveland, OH)

Potassium EDTA solution

Applied Biosystems (Warrington, UK)

Protease Inhibitor Cocktail

Sigma Chemical Co. (St. Louis, MO)

Sodium Acetate (NaAc)

Fisher Scientific (Pittsburg, PA)

Sodium acetate buffer (3 M) pH = 3.8

Perkin Elimer (Warrington, UK)

s-β(4-Pyridylethyl)-L-Cysteine (PEC)

Sigma Chemical Co. (St. Louis, MO)

Tetrahydrofuran (THF)

Sigma Chemical Co. (St. Louis, MO)

Trifluoroacetic acid (TFA)

Pierce (Rockford, IL)

Water, HPLC Grade

Honeywell Burdick&Jackson™
(Muskegon, MI)

ε-N-(Furoyl-methyl)-L-lysine·2HCl

NeoMPS, Inc. (San Diego, CA)

(Furosine Dihydrochloride)

2.2 Case-Control Study Design
Clinically documented control and AMD blood donors were recruited
prospectively between 2005 and 2008 from the Cole Eye Institute, Cleveland
Clinic Foundation with the approval of each Institutional Review Board and
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according to Declaration of Helsinki principles. All patients received a
comprehensive eye examination by a clinician and provided written informed
consent. All human identifiers were removed from blood specimens and were
encoded to protect donor confidentiality. AMD disease progression was
categorized based on fundus examination and patients were included in the
study from AREDS (The Age-Related Eye Disease Study Group) AMD
categories 2, 3, 4. Briefly, AMD category 2 patients exhibited early-stage disease
with multiple small drusen, single or nonextensive intermediate drusen (63-124
µm), RPE pigmentary abnormalities, or any combination of these, in one or both
eyes and visual acuity of 20/30 or better in both eyes. AMD category 3 patients
exhibited mid-stage disease with at lease one eye with visual acuity 20/30 or
better and one large drusen (125 µm), extensive intermediate drusen or
geographic atrophy that did not involve the macula or any combination of these.
Category 3 patients lacked advanced AMD in either eye. AMD category 4
patients exhibited advanced AMD with substantial choroidal neovascularization
(CNV) or geographic atrophy (GA) involving the macula in one or both eyes.
Control donors lacked macular drusen and exhibited no clinical evidence of any
retinal disorder. Plasma were prepared from blood specimens and stored frozen
until analysis as described below.

2.3 Human Plasma Preparation
Nonfasting blood specimens were collected in 4 ml BD Vacutainer® spraycoated K2EDTA tubes and plasma was prepared within 6 hours and aliquotted to
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vials containing butylated hydroxytoluene (BHT; 1 mg/ml plasma) and a protease
inhibitor cocktail (10 µl/ml plasma) (Gu et al., 2003). The final concentrations of
these additives in plasma were: BHT, 22 µg/ml; AEBSF (serine protease
inhibitor), 1mM; aprotinin (serine protease inhibitor), 0.8 µM; leupeptin (serine
and cysteine protease inhibitor), 20 µM; bestatin (aminopeptidase inhibitor), 40
µM; pepstatin A (acid protease inhibitor), 15 µM; and E-64 (cysteine protease
inhibitor), 14 µM. The plasma was flushed with argon, quench-frozen in liquid
nitrogen immediately and stored at - 80°C. Storage time ranged from 4 - 34
months and averaged 13 month. All samples were frozen and thawed only once.

2.4 Plasma Protein Quantification by Amino Acid Analysis
Phenylthiocarbamyl (PTC) and AccQ•Tag™ amino acid analysis were
used to quantify plasma proteins. The following steps of sample preparation and
analysis were performed: (1) precipitation of plasma proteins; (2) HCl hydrolysis
of the plasma proteins; (3) PTC or AccQ•Tag™ derivatization of the amino acids;
(4) chromatographic analysis, and (5) quantitative data interpretation.

2.4.1 Precipitation of Plasma Protein
To obtain the most accurate amino acid analysis data, protein samples
should be homogeneous, free of salts and detergents. The solubility of proteins is
greatly influenced by the dielectric constant of the solution. In general, solvent
molecules with large dielectric constants, such as water, can stabilize the
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interaction between themselves and protein molecules and favor the dissolution
of protein. On the other hand, organic solvents with small dielectric constant,
such as acetone, discourage the dispersion of protein molecules in the media.
Thus, the solubility of proteins can be lowered and precipitation can be induced
by lowering the effective dielectric constant of the media. This is commonly
achieved by adding a water soluble solvent such as acetone to an aqueous
solution of protein.
Acetone precipitation: Plasma samples (200 µl, ~ 11 mg) were transferred
to 6 × 50 mm hydrolysis tubes and protein was precipitated by adding 2 volumes
(400 µl) of cold acetone. The tube was sealed with Parafilm, the solution was
mixed and incubated 10-20 min at 4°C, then centrifuged briefly (10,000 rpm,
table top centrifuge) to pellet protein and the supernatant was carefully removed
and discarded. The pellet was washed once with 400 µl of 67% acetone and
vacuum dried (Crabb et al., 1997).

2.4.2 HCl Hydrolysis
Key to the success of protein amino acid analysis is the hydrolysis of the
polypeptides into free amino acids. Complete hydrolysis was originally performed
by heating the protein sample in constant-boiling HCl. However, vapor-phase
hydrolysis methods are now often preferred because they are more rapid than
the liquid-phase methods, and they reduce the possibility of introducing
background contaminants with HCl.
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Hydrolysis: A diamond pencil was used to etch identity numbers on the
tubes. After drying the sample, 60 µl of 6 M HCl was added to each hydrolysis
tube to cover the pellet and the tubes were placed into a 40 ml screw-cap vial
containing 300 µl of 6 M HCl and a few crystals of phenol (~ 1-2 mg). The 40 ml
vial was capped with a modified Mininert slide valve and connected to vacuum
and argon flush systems via a three-way stopcock. Argon gas and vacuum were
alternatively donated into the vial three times to effectively remove the air from
the vial (Crabb et al., 1997). The vial was finally sealed under vacuum and was
heated at 110°C for 16 hours to vapor phase hydrolyze the protein pellets.
Following hydrolysis, the Mininert valve was opened carefully in a fume hood to
release the HCl vapor and the hydrolysis tubes were vacuum dried, flushed with
Argon and stored at - 20°C until analysis. Bovine serum albumin (BSA) (~ 220 µg)
obtained from National Bureau of Standard (NBS) was also hydrolyzed as a
quantitative standard and stored in the same way as the plasma samples. For
PTC amino acid analysis, hydrolysates were resuspended in H2O (600 µl). After
PTC amino acid analysis, the hydrolysates were vacuumed dried and
resuspended in 50 µl H2O for all subsequent analyses.

2.4.3 Derivatization of the Amino Acids
2.4.3.1 PTC Amino Acid Analysis
Phenylthiocarbamyl amino acid analysis (PTC-AAA) utilizes precolumnderivatization with phenylisothiocyanate (PITC) followed by reversed-phase high
performance liquid chromatography (RP-HPLC) (Crabb et al., 1997).
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Chemicals: The derivatization reagents, 5% PITC in n-heptane and N, Ndiisopropylethylamine (DIEA), were purchased from Applied Biosystems.
Methanol was HPLC grade from Fisher Scientific. Standard amino acids
(Standard H) for the calibration were obtained from Pierce. Sodium acetate buffer
(3 M, pH = 3.8 and pH = 5.5) separation grade, were purchased from Perkin
Elimer. The later buffer was also made by ourselves. Potassium EDTA solution
(50 mg/ml) was obtained from Applied Biosystems. Water (Burdick&Jackson™)
and acetonitrile (Fisher Scientific) were both HPLC grade.
PTC Derivatization: After hydrolysis, the hydrolyzed amino acids were
converted into phenylthiocarbamyl (PTC) derivatives for UV visibility (Figure 2.1).
The derivatization was accomplished by coupling the amino group of the amino
acid with PITC in basic solutions. Plasma hydrolysate (5 µl, ~ 82 µg protein) was
transferred to a clean Eppendorf tube and dried. The sample was neutralized by
adding 100 µl of the base DIEA in methanol (1:2 v/v) and re-dried. The PITC
coupling reagent (PITC:DIEA:methanol, 2:2:7) was added (75 µl per tube) and
the mixture was incubated at 25°C for 20 minutes. After incubation, the samples
were dried and analyzed immediately, or stored at -20°C under argon until
analysis. NBS-BSA standard samples were derivatized in the same way.
Standard amino acids (Pierce standard H) were diluted to 60 pmol/µl in water
and stored at -20°C until use. Standards H (20 µl, 1.2 nmol) was dried and redried from DIEA (20 µl) as above. The PITC Coupling Reagent (15 µl) was added
and incubated at 25°C for 20 minutes, then the derivatized standard amino acids
were dried down and analyzed or stored as above.
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HPLC analysis: The analysis of PTC-derivatized amino acids was
performed on an Agilent 1100 HPLC system coupled in-line with a UV Detector
(GILSON, Model 116). Derivatized hydrolysates were dissolved in transfer buffer
(240 µl) (29 mM sodium acetate, pH 5.2, 0.1 mg/ml K3EDTA) and 8 µl (~ 2.7 µg)
was injected onto a HAISIL PTC C18 reversed-phase column (220 × 2.1 mm,
Applied Biosystem) using gradient elution (Table 2.1). Column temperature was
controlled at 30°C. The PTC-derivatized amino acids were monitored with the UV
detector at λ = 254 nm. Analyses were performed in duplicate. Standard H amino
acids (480 pmol) were analyzed using the same chromatographic method and
repeated six times to obtain average results for calibrating the system.
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Figure 2.1. PTC Derivatization. Phenylthiocarbomyl (PTC) amino acids were
formed by derivatizing amino acids with phenylisothiocyannate (PITC) under
basic condition (A). Side products were also produced by the reaction of PITC
with other amino groups (B) (Reproduced from Crabb et al., 1997).
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Table 2.1. Gradient Profile for PTC Amino Acid Analysis
Analysis Time (min)

0

6

8

17.5

19.5

Sovent A (%)

95

85

74

64

0

Sovent B (%)

5

15

26

36

100

Solvent A: 3% (v/v) acetonitrile, 50 mM sodium acetate, pH 5.4
Solvent B: 70% (v/v) acetonitrile, 32 mM sodium acetate, pH 6.1
Flow Rate: 300 µl/min

2.4.3.2 AccQ•Tag™ Amino Acid Analysis
The AccQ•Tag™ Ultra Reagent (6-aminoquinolyl-N-hydroxysuccinimidyl
carbamate,

or

AQC)

is

an

N-hydroxysuccinimide-activated

heterocyclic

carbamate, an amine derivatizing compound. It converts both primary and
secondary amino acids to stable derivatives, as illustrated in Figure 2.2 (Cohen
et al., 1993; Ward et al., 1996).
Chemicals: The AccQ•Tag™ Ultra derivatization kit, including AccQ•Tag™
Ultra borate buffer, AccQ•Tag™ Ultra reagent powder, AccQ•Tag™ Ultra reagent
diluent were purchased from Waters, as were the AccQ•Tag™ Ultra Eluent A
concentrate and AccQ•Tag™ Ultra Eluent B. Amino acid hydrolysate standards
(Thermo Scientific) were diluted to 500 pmol/µl in water and stored at -20°C until
use. Different dilution ratios were used when preparing the calibration curve.
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Figure 2.2. AccQ•Tag™ Derivatization. The AccQ•Tag™ Ultra Reagent
reacts rapidly with primary and secondary amino acids to yield highly stable
urea. The structure of the derivatizing group is the same for all amino acids,
adding the UV absorbance character. Excess reagent hydrolyzes to yield 6aminoquinoline (AMQ), a non-interfering by-product (Reproduced from Cohen
et al., 1993).

AccQ•Tag™ derivatization: The Waters AccQ•Tag™ derivatization reagent
was prepared by adding the appropriate AccQ•Tag™ Ultra reagent diluent (1ml)
to the AccQ•Tag™ power reagent provided in the kit, then the solution was
heated for 10 minutes at 55°C. Plasma hydrolysates (~ 3.53 µg protein in 10 µl
water) were transferred to reaction vials (Waters) and the AccQ•Tag™ Ultra
borate buffer (70 µl) was added to adjust the pH between 8 and 10. Then
reconstituted AccQ•Tag™ Reagent (20 µl) was added, mixed and heated for 10
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minutes at 55°C. The standard amino acid prepared was derivatized in a similar
manner. AccQ•Tag™ derivatized samples were analyzed using the Waters
ACQUITY Ultra Performance LC® (UPLC®) system using 1 µl

injections for

optimum resolution and sensitivity and the AccQ•Tag™ Ultra Column (100 × 2.1
mm) (Waters) with gradient elution (Table 2.2). AccQ•Tag amino acids were
detected with the ACQUITY UPLC® Tunable UV (TUV) Detector at 260 nm.
Table 2.2. Gradient Profile for AccQ•Tag™ Amino Acid Analysis
Analysis Time (min)

0

0.54

5.74

7.74

8.04

8.05

Sovent A (%)

99.9

99.9

90.9

78.8

40.4

10.0

Sovent B (%)

0.1

0.1

9.1

21.2

59.6

90.0

Solvent A: Dilution of concentrated AccQ•Tag™ Ultra Eluent A (140 mM
sodium acetate containing 17 mM triethylamine, pH 5) with H2O
in the ratio
of 1 : 19
Solvent B: AccQ•Tag™ Ultra Eluent B (60% acetonitrile, 40% water)
Flow rate: 700 µl/min

Furosine (ε-N-furoylmethyl-L-lysine) (NeoMPS, Inc. San Diego, CA), a
form of glycated lysine, is detectable following acid hydrolysis of the Amadori
compound. In this thesis, furosine was quantified by AccQ•Tag™ amino acid
analysis using the method described above. The plasma hydrolysates (~ 15 µg
protein) were dried in reaction vials, the AccQ•Tag™ Ultra borate buffer (35 µl)
and the reconstituted AccQ•Tag™ Reagent (20 µl) was added, mixed and heated
for 10 minutes at 55°C, 10 µl out of the total 55 µl was injected on the column.
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The gradient was modified to optimize the resolution of furosine peak 3 (Table
2.3).
Table 2.3. Gradient Profile for Quantification of Furosine using
AccQ•Tag™ Amino Acid Analysis
Analysis Time (min)

0

0.54

4.24

5.00

7.80

7.90

8.50

8.51

Sovent A (%)

99.9

99.9

94.4

89.9

75.0

32.0

32.0

10.0

Sovent B (%)

0.1

0.1

5.6

10.1

25.0

68.0

68.0

90.0

Solvent A: Dilution of concentrated AccQ•Tag™ Ultra Eluent A (140 mM
sodium acetate containing 17 mM triethylamine, pH 5) with H2O in
the ratio
of 1 : 19
Solvent B: AccQ•Tag™ Ultra Eluent B (60% acetonitrile, 40% water)
Flow rate: 700 µl/min

2.4.3.3 Data Analysis
Quantification of plasma protein: For unknown plasma samples, the amino
acid residue weights were multiplied by the pmol analyzed for each amino acid
and then summed to obtain the amount of protein analyzed. The plasma protein
concentration was determined by multiplying the amount analyzed by the ratio of
amount applied to the analyzer.
Quantification of BSA: For homogeneous BSA samples we used the pmol
analyzed for each amino acid and the known protein composition to determine
pmol protein based on each amino acid. The amount analyzed was estimated by
averaging each of the residue estimates of pmol protein, then values were
discarded that were greater than 15% from the mean. The final pmol protein
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analyzed was determined by averaging the remaining residue values. The BSA
sample concentration was determined by multiplying the pmol protein by the ratio
of the sample applied to the analyzer. BSA was converted to micrograms by
multiplying pmol protein by the molecular weight (MW = 66,328).
Quantification of furosine: Large amounts of plasma hydrolysates were
analyzed in order to quantify furosine, which is usually present in plasma in
relative low amounts. A linear response of AccQ•Tag™-derivatized amino acids,
including furosine, was obtained in the range of 0.5 pmol to 2000 pmol. Amounts
out of this range were discarded. Ile and Leu were discarded because they are
co-elute with mono-derivatized furosine. Ser and Thr are partially destroyed by
HCl hydrolysis and Met is subject to oxidation, so these residues were not
included in the final calculation. The remaining residues were selected based on
values within 15% of the mean. Furosine concentration relative to protein was
calculated by dividing the amount of furosine (pmol) by the corresponding
amount of plasma protein (µg).

2.5 Quantification of Advanced Glycation End-Products (AGEs)
Carboxymethyllysine (CML), pentosidine and argpyrimidine were analyzed
in plasma protein HCl hydrolysates following a two-step HPLC separation using
mass spectrometry and fluorimetry.
Chemicals: CML was purchased from NeoMPS, Inc. (San Diego, CA).
Pentosidine was purchased from International Maillard Reaction Society (IMARS)
(Case Western Reserve University, Cleveland, OH). Argpyrimidine was obtained
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from Dr. Ram Nagaraj (Case Western Reserve University). s-β(4-Pyridylethyl)-LCysteine (PEC) (Sigma) was used as internal standard to correct for losses
during chromatography. Trifluoroacetic acid (TFA) (Pierce), acetic acid (AA)
(Trace metal grade, Fisher Scientific), tetrahydrofuran (THF) (Sigma), sodium
acetate (NaAc) (Anhydrous, Fisher Scientific), ammonium acetate (HPLC grade,
J.T. Baker), waters (HPLC grade, Burdick&Jackson™), and acetonitrile (HPLC
grade, Fisher Scientific) were used to prepare mobile phases.
HPLC System I: A Hypercarb™ porous graphitic carbon column (5 µm
particles, 50 × 10 mm) (Thermo Scientific) was employed for the initial
chromatography for AGEs quantification. The Hypercarb™ column is particularly
useful for the separation of highly polar compounds which are difficult to retain on
C18 reverse phases. Plasma hydrolysate (40 µl, ~ 8 mg protein) was analyzed
using gradient separation (Table 2.4), a flow rate of 1 ml/min, a column
temperature of 30°C, and an Agilent 1100 HPLC system. The HPLC eluent was
directed first to a Waters™ 474 Scanning Fluorescence Detector (λexcitation /
λemission = 335/385 nm) to quantify argpyrimidine and pentosidine which are
naturally fluorescent. Following fluorescence detection, the eluent was split with
80% directed to a fraction collector and 20% directed to a SCIEX API 3000 triple
quadrupole electrospray mass spectrometer (Applied Biosystem). Glycation
markers were detected in the positive ion mode using tandem mass spectrometry
and multiple reaction monitoring (MRM), in which both parent ions and fragment
ions were monitored in Q1 and Q3, respectively (Figure 2.3). Different
fragmentation voltages were tested to optimize the MRM transitions for

53

quantitation. The most intense fragment ion and the precursor ion were used to
monitor the AGEs. Tuning was also done with collision energy in order to obtain
the most favorable signal to noise ratio. Ionization source temperature was
425°C, and the programmed parameters and collision energies were optimized to
± 0.1 Da and ± 1 volts (Table 2.5).

Table 2.4. Gradient Profile for Separation of AGEs on the Hypercarb™
Column in HPLC System I
Analysis Time (min)

0

3.8

4

8

12

13

16

Sovent A (%)

100

95

82

70

70

0

0

Sovent B (%)

0

5

18

30

30

100

100

Solvent A: H2O, 0.1% (v/v) trifluoroacetic acid
Solvent B: Acetonitrile, 0.1% (v/v) trifluoroacetic acid
Flow rate: 1 ml/min

54

Figure 2.3. Transition Ions for Multiple Reaction Monitoring (MRM) of
CML, Pentosidine, Argpyrimidine and Pyridylethyl-Cysteine.
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Table 2.5. Mass Spectrometric Multiple Reaction Monitoring Detection

Analyte

Parent ion
(Q1)
m/z (Da)

Fragment
ion (Q3)
m/z (Da)

DP*
(Volts)

FP*
(Volts)

CE*
(Volts)

CML

205.1

84.1

35

250

26

Pentosidine

379.2

187.2

40

300

45

Argpyrimidine

255.2

237.3

35

250

20

Pyridylethyl-Cysteine
(Internal Standard)

227.3

106.1

25

250

27

* DP, Declustering Potential; FP, Focusing Potential; CE, Collision Energy.

CML, pentosidine and argpyrimidine standards were injected together with
the PEC internal standard on the Hypercarb™ column. All of the standards were
separated well in the chromatography in the absence of a plasma hydrolysate
(Figure 2.4). CML eluted at 7.26 min, at ~ 4.4% solvent B, PEC eluted at 8.82
min, ~ 7.8% solvent B, and argpyrimidine and pentosidine eluted at 13.12 min
and 14.62 min, respectively, with isocratic 30% solvent B. These standards
spiked with plasma hydrolysate (~ 8 mg protein) (Figure 2.5) resulted in shifted
retention times for CML and pentosidine while argpyrimidine and PEC remained
largely unchanged. This caused argpyrimidine and pentosidine to co-elute. In
addition, numerous fluorescent substances co-eluted with argpyrimidine and
pentosidine. A second chromatography step was incorporated to positively
identify all compounds of interest.
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Figure 2.4. HPLC System I Separation of CML, Argpyrimidine and
Pentosidine Standards and PEC (internal standard) on a Hypercarb™
Column in the Absence of a Plasma Hydrolysate.
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Figure 2.5. HPLC System I Separation of CML, Argpyrimidine and
Pentosidine Standards and PEC (internal standard) on a Hypercarb™
Column in the Presence of Plasma Hydrolysates.

58

For experimental analyses, plasma hydrolysate (40 µl, ~ 8 mg protein) was
spiked with 15 pmol of PEC standard and separated on HPLC System I. Three
fractions were collected: CML was collected from 4.2 to 6.0 min (~ 1.8 ml);
argpyrimidine and pentosidine were collected in the same fraction from 12.0 to
13.8 min (~ 1.8 ml); and PEC was collected from 8.4 to 9.0 min (~ 600 µl).
Fractions from HPLC System I were vacuum dried and stored at - 80ºC until
further analysis.
HPLC System II: Chromatography fractions from HPLC System I were
re-fractionated on HPLC System II using a Cogent Diamond Hydride™ Column
(4.2 µm particles, 150 × 2.1 mm). The Cogent Diamond Hydride™ column is a
silica hydride-based stationary phase that separates very polar compounds in
aqueous normal phase (Pesek et al., 2008). Two mobile phases were used in
HPLC System II to optimize the resolution of each analyte of interest. Fractions
containing CML were re-chromatographed using aqueous acetic acid/acetonitrile
solutions (Table 2.6) and CML was detected and quantified by tandem MS, using
MRM at 205.1 / 84.1 m/z and the same parameters as in HPLC System I (except
the ionization source temperature was 490°C). Calibration curves with the CML
standard were prepared at five levels: 10, 20, 30, 40, 50 pmol. Quantification of
CML was based on peak area and the external standard calibration curve.
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Table 2.6. Gradient Profile for CML on the Cogent Diamond Hydride™
Column in HPLC System II
Analysis Time (min)

0

3

5

7

8

11.5

13.6

Sovent A (%)

5

5

45

45

52

52

100

Sovent B (%)

95

95

55

55

48

48

0

Solvent A: H2O, 0.1% (v/v) acetic acid
Solvent B: Acetonitrile, 0.1% (v/v) acetic acid
Flow rate: 400 µl/min

HPLC System I chromatography fractions containing PEC, argpyrimidine
and pentosidine were re-chromatographed using ammonium acetate/acetonitrile
solvents and gradient separation (Table 2.7). HPLC separation was couple with
fluorescence detection followed by tandem MS as for CML. PEC was monitored
by MRM at 227.3 / 106.1 m/z using the same mass spectrometry conditions as in
Table 2.5 and the calibration curve developed with five amounts: 3, 6, 9, 12, 15
pmol. Pentosidine and argpyrimidine were monitored using fluorimetry (λex / λem =
335/385 nm) coupled with MRM mass spectrometry (pentosidine using 379.2 /
187.2 m/z; argpyrimidine using 255.2 / 237.3 m/z) and calibration curves
developed at 2, 4, 6, 8, 10 pmol. The mass spectrometric signal for pentosidine
was less sensitive and less stable than the fluorescent signal, therefore the
quantification of pentosidine was based on the fluorescence peak area and the
external standard calibration curve.
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Table 2.7. Gradient Profile for PEC, Pentosidine and Argpyrimidine on
the Cogent Diamond Hydride™ Column in HPLC System II
Analysis Time (min)

0

0.5

3

13

15

Sovent A (%)

0

10

10

90

100

Sovent B (%)

100

90

90

10

0

Solvent A: H2O, 10 mM ammonium acetate, pH 6.0
Solvent B: 80% (v/v) ACN, 10 mM ammonium acetate, pH 6.0
Flow Rate: 400 µl/min

2.6 Quantification of CEP Adducts and CEP Autoantibody
Competitive ELISA was performed by Dr. Jiayin Gu to determine CEP
adduct concentrations in AMD and control plasma as described elsewhere (Gu et
al., 2003; Gu et al., 2009). Briefly CEP-BSA was used as coating agent and
CEP-HSA as reference standard, and purified rabbit anti-CEP polyclonal
antibody (pAb) as primary antibody.

The reference standard curve was

generated by ten serial dilutions of CEP-HSA with initial pyrrole concentration
8692.5 pmol/mL and a 0.2 serial dilution factor. Sample plasma was also serial
diluted with PBS and a 0.2 dilution factor. Up to 6 dilutions were made for each
plasma sample.
Direct ELISA was performed by Dr. Jiayin Gu to determine anti-CEP
autoantibody titer in AMD and control plasma (Gu et al., 2003; Gu et al., 2009).
Plasma samples were diluted 10 times and added to 3 CEP-BSA coated wells
and 3 BSA coated wells. The titer was calculated as the ratio (A/A0) of the mean
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absorbance of 3 CEP-BSA coated wells (A) vs the mean absorbance of 3 BSA
coated wells (A0).

2.7 Statistics
Continuous measures were summarized using means, standard deviations,
medians and interquartile ranges. Differences in plasma CML and pentosidine
concentrations between control and AMD patients were evaluated using two
sample t-tests in Excel 2003 (Microsoft® Office). To evaluate the relationship
between CML and pentosidine with AMD susceptibility, a logistic regression
model was fit with both variables as predictors using SAS 9.1 software (SAS
Institute, Cary, NC). C-statistics measured the model’s ability to discriminate
between AMD and controls, and odds ratios (ORs) showed the change in risk of
AMD based on the predictors. ORs, c-statistics and p-values were determined
based on log-transformed marker concentrations. Validation of c-statistics was
performed using 2000 bootstrap (random) resamplings to calculate empirical
95% confidence intervals (CI) and by performing 10-fold cross-validation. Pvalues < 0.05 were considered significant. Sensitivity and specificity were
calculated to maximize the sum of the two values using receiver operating
characteristic (ROC) curves constructed with SAS 9.1 from the output of logistic
regression analysis fit with either single AGE marker or CEP adducts, or the
combination of the AGE markers and CEP adducts. C-statistics and p-values
comparing ROC curves were determined with SAS 9.1. For association analyses
of combined effects of plasma AGEs with CEP adducts, ORs with 95% CI and
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Fisher Exact p-values were calculated with SAS 9.1 software. Pearson’s
correlation analysis in Minitab Release 15 (Minitab Inc., PA) was used to
compare concentrations of AGE markers with plasma donor age.
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CHAPTER III
RESULTS

3.1 Plasma Protein Quantification
Vapor phase HCl hydrolysis was performed to cleave the proteins into
amino acids and sixteen of the common twenty amino acids were quantified by
PTC Amino Acid Analysis and by AccQ•Tag™ Amino Acid Analysis. Quantified
amino acids include Asp, Glu, Ser, Gly, His, Arg, Thr, Ala, Pro, Tyr, Val, Met, Ile,
Leu, Phe, and Lys. Trp and Cys are destroyed by HCl hydrolysis, Ser and Thr
are partially destroyed, Ile and Val are slow to cleave, Met is subject to oxidation,
and Asn and Gln are deamidated.
Protein Quantification by PTC Amino Acid Analysis. Replicate PTC amino
acid analyses were performed on plasma protein hydrolysates using standard H
(Pierce) for calibration and hydrolysates of NBS-BSA for quantitative validation of
the entire procedure (Figure 3.1). The average peak area was calculated for
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each amino acid from multiple injections of Standard H amino acids and
response factors were calculated for each amino acid by dividing the average
peak area by pmole of amino acid. PTC amino acid analysis yielded average
relative standard deviations (RSD) of 0.25% for retention time and 5.02% for
response factors for n = 6 replicates of Standard H amino acids performed eight
times over 14 days (Table 3.1). The amount of protein in plasma hydrolysates
and NBS-BSA hydrolysates was obtained by dividing the peak area from each
amino acid by the response factors determined by calibration.
Protein Quantification by AccQ•Tag™ Amino Acid Analysis. Replicate
AccQ•Tag™ amino acid analyses were performed on plasma protein
hydrolysates using standard amino acids (Thermo Scientific) for calibration and
NBS-BSA hydrolysates to validate quantification. Calibration was achieved by
analyzing AccQ•Tag™ derivatized amino acid standards (Figure 3.2) at six
different amounts (1-50 pmol) in 3 replicates each. Reproducibility of retention
times and the linearity of the calibration curves for each amino acid are shown in
Table 3.2. AccQ•Tag™ Amino Acid Analysis yielded average RSDs of 0.18% for
retention times and 5.1% for response factors in n = 6 replicates of amino acid
standards performed twelve times over 20 days. The amount of protein in plasma
protein and NBS-BSA hydrolysates was determined by dividing peak areas by
response factors.
Examples of quantitative results from PTC amino acid analysis of NBSBSA and plasma protein hydrolysates are shown in Table 3.3 and 3.4,
respectively. Both PTC and Waters AccQ•Tag™ derivatized amino acid analysis
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were performed in duplicate for each plasma protein sample, and the results are
presented in Table 3.5 and 3.6, respectively. The quantitative results agree well
and difference in protein quantification for the two methods was less than 10%
(Table 3.7). Since carboxymethyllysine, argpyrimidine and pentosidine are
glycation modifications of arginine and lysine, the concentration of arginine (R)
and lysine (K) were also quantified in Table 3.8.
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Figure 3.1. PTC Amino Acid Analysis—Representative Chromatography.
A: Standard H Amino Acids (480 pmol); B: NBS-BSA hydrolysate (2.2 µg
analyzed); C: Plasma protein hydrolysate (1.2 µg analyzed).
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Figure 3.2. AccQ•Tag™ Amino Acid Analysis — Representative
Chromatography. A: Standard amino acids (10 pmol); B: NBS-BSA
hydrolysate (36.7 ng analyzed); C: Plasma protein hydrolysate (39.2 ng
analyzed). * Derivatization byproducts.
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Table 3.1. Reproducibility of Retention Times and Response Factors in
PTC Amino Acid Analysis. Sample = Standard H Amino Acids (480 pmol)
(Pierce), n = 48 analyses over 14 days.
Amino
acids

Retention Time
(min)

RSD

Response Factor
(×10-1)

RSD

ASP

(D)

3.12

0.55%

1.08

11.99%

GLU

(E)

3.40

0.52%

1.27

8.05%

SER

(S)

4.34

0.41%

1.34

4.47%

GLY

(G)

4.77

0.39%

1.55

4.01%

HIS

(H)

5.61

0.42%

1.32

4.97%

ARG

(R)

6.38

0.33%

1.16

7.25%

THR

(T)

6.66

0.30%

1.29

3.11%

ALA

(A)

6.86

0.28%

1.62

3.04%

PRO

(P)

7.46

0.25%

1.72

3.09%

TYR

(Y)

11.92

0.10%

1.57

3.88%

VAL

(V)

12.64

0.08%

1.48

3.78%

MET

(M)

13.00

0.08%

1.52

2.91%

ILE

(I)

14.93

0.08%

1.51

3.88%

LEU

(L)

15.17

0.07%

1.71

7.93%

PHE

(F)

16.53

0.07%

1.53

3.42%

LYS

(K)

18.30

0.11%

2.85

4.47%

Average

0.25%

Average

5.02%

*RSD = Relative Standard Deviation
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RSD, relative standard deviation.

Table 3.2. Reproducibility of Retention Times, Response Factors and Linear Correlation Between
Peak Area and the Amount of Analytes in AccQ•Tag™ Amino Acid Analysis. Sample = Standard Amino
Acids (Thermo Scientific), n = 72 analyses over 20 days.
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The accuracy of the AAA system was verified using a known amount of bovine serum albumin available from
National Bureau of Standards (NBS-BSA). The above data is from PTC-AAA; the same calculation method
was used with AccQ•Tag™ AAA.

Table 3.3. Quantification of BSA by Amino Acid Analysis
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The above data is from PTC-AAA; the same calculation method was used with AccQ•Tag™ AAA.

Table 3.4. Quantification of Plasma Proteins by Amino Acid Analysis
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STD, standard deviation; RSD, relative standard deviation.

Table 3.5. Summary of Plasma Protein Concentrations Determined by PTC Amino Acid Analysis
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STD, standard deviation; RSD, relative standard deviation.

Table 3.6. Summary of Plasma Protein Concentrations Determined by AccQ•Tag™ Amino Acid Analysis
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STD, standard deviation; RSD, relative standard deviation.

Table 3.7. Comparison of the PTC and AccQ•Tag™ Amino Acid Analysis
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STD, standard deviation; RSD, relative standard deviation.

Table 3.8. Summary of Average Plasma Arginine and Lysine Concentration Determined by PTC and
AccQ•Tag™ Amino Acid Analysis

Furosine was quantified in each plasma protein sample using AccQ•Tag™
amino acid analysis (Figure 3.3) and the results are presented in Table 3.9.
Furosine contains a primary and a secondary amino group (Figure 1.11) and
both are derivatized by the AccQ•Tag™ reagent, yielding two different monoderivatized forms and a di-derivatized form. As shown in Figure 3.3, furosine
peaks 1 and 2 exhibit relatively close retention times (7.1 min and 7.2 min); these
peaks may represent the mono-derivatized forms of furosine. Furosine peak 3
elutes much later, is less polar than peaks 1 and 2 and therefore may be the
di-derivatized form of furosine. Different amounts of furosine (2 to 10 pmol) were
derivatized, the peak areas of furosine peaks 1, 2 and 3 were integrated, and the
response factors for each peak found to be constant under the derivatization
conditions used. Furosine peaks 1 and 2 overlapped with Ile and Leu and
therefore could not be used for quantification. Furosine peak 3 was well
separated from other amino acids and was therefore used for quantification of
furosine in plasma protein hydrolysates. The low concentration of furosine in
plasma required a relatively large amount of plasma hydrolysate to detect
furosine in the analysis. Plasma protein concentration was calculated based on
select amino acids in the plasma protein hydrolysate (as described in methods)
including H, R, G, D, E, A, P, K, Y, V, F. Those residues yielding amounts within
±15% of the mean were used for protein quantification. Usually protein
quantification for the furosine analyses was based on 5 or 6 residues (H, R, P, Y,
V, F). The protein concentration of all samples during the furosine analysis was
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quantified in good agreement with the previous results shown in Table 3.6
(average difference ~ 1.7%, n = 90).
The average concentration of furosine in the normal control samples (n =
30) was 1.03 ± 0.11 pmol/µg, which is very close to 1.05 ± 0.11 pmol/µg
determined for all the AMD samples (n = 60). Among all the AMD patients, there
were five diabetic patients and the average furosine concentration for these
samples was 1.24 ± 0.05 pmol/µg, ~ 20% higher than the controls (Figure 3.4).
There was no apparent difference in furosine concentration between the control
donors and AMD patients without diabetes (n = 55, 1.03 ± 0.09 pmol/µg). Overall,
the results for furosine showed minimal if any unknown diabetic patients in our
study population.
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Figure 3.3. Representative Chromatography for Quantification of
Furosine using AccQ•Tag™ Amino Acid Analysis. A: Standard amino
acids (10 pmol); B: Furosine standard (5 pmol); C: Furosine (~ 4.2 pmol) was
quantified in plasma hydrolysate (2.7 µg). The acetonitrile gradient was
modified to optimize resolution of furosine peak 3. * Derivatization byproducts.
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STD, standard deviation; RSD, relative standard deviation.

Table 3.9 Quantification of Furosine in Plasma Protein Sample using AccQ•Tag™ Amino Acid Analysis

Figure 3.4. Quantification of Furosine in Plasma Protein Samples.
Furosine was quantified by AccQ•Tag™ amino acid analysis from control (n =
30) and AMD (n = 60) plasma donors, including non-diabetes (n = 55) and
diabetes (n = 5) are shown with mean (Δ) results ± standard deviation (SD)
and with median (○) results ± first and third quartiles (Q1, Q3). The data is
presented in Table 3.9. P-values (two sided t-Test) were determined from logtransformed concentrations.
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3.2 Quantification of AGEs in Plasma Hydrolysate
Plasma protein hydrolysates were assayed for AGEs by a two-step HPLC
process. Only protein-bound AGEs were analyzed as free AGEs were washed
away during acetone precipitation of the plasma proteins. A representative
chromatography from HPLC System I (Figure 3.5) shows that CML and the
internal standard (PEC) are well resolved but that argpyrimidine and pentosidine
co-elute. Therefore, fractions collected from HPLC System I were rechromatographed in HPLC System II (Figure 3.6 and 3.7) to separate
argpyrimidine and pentosidine (Figure 3.8). Argpyrimidine in plasma hydrolysates
was at or below the detection limits of the analytical system and therefore
quantification of the AGEs was not pursued further. Representative calibration
curves for CML, pentosidine and PEC (internal standard) are shown in Figure 3.9.
Excellent linearity was observed between peak area and amount analyzed for all
three amino acids. The amount of CML, PEC and pentosidine were calculated
with the integrated peak area and the external calibration curve. The recovery of
PEC on two HPLC systems was calculated by dividing the final amount detected
in the HPLC System II by the original 15 pmol added into the plasma hydrolysate
before the injection on HPLC System I. The average recovery of the PEC was
70.1% ± 0.13 (mean ± SD, n = 90). The measured amounts of CML and
pentosidine were corrected based on the recovery of PEC. The amounts of CML,
pentosidine and PEC found in each plasma protein hydrolysate are presented in
Table 3.10.
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Figure 3.5. HPLC System I Representative Chromatography of CML,
Argpyrimidine and Pentosidine Standards and PEC (internal standard) in
the Presence of Plasma Hydrolysates.
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Figure 3.6. HPLC System II Representative Chromatography of CML in
Acetic Acid/Acetonitrile Solvents. (A) CML standard (20 pmol); (B) CML
from HPLC System I fractions from a normal control subject; (C) CML from
HPLC System I fractions from an AMD patient. Detection: mass spectrometry
using multiple reaction monitoring (MRM) at 205.1 / 84.1 m/z, and an
ionization source temperature of 490°C.
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Figure 3.7. HPLC system II Representative Chromatography of PEC in
Ammonium Acetate/Acetonitrile Solvents. (A) PEC standard (6 pmol); (B)
Spiked PEC from HPLC System I fractions from a normal control subject; (C)
Spiked PEC from HPLC System I fractions from an AMD patient. Detection:
mass spectrometry using multiple reaction monitoring (MRM) at 227.3 / 106.1
m/z, and an ionization source temperature of 490°C.
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Figure

3.8.

HPLC

System

II

Representative

Chromatography

of

Pentosidine and Argpyrimidine in Ammonium Acetate/Acetonitrile
Solvents. (A) Pentosidine standard (4 pmol); (B) Argpyrimidine standard (8
pmol); (C) Pentosidine and argpyrimidine fractions from HPLC System I from a
normal control subject; (D) Pentosidine and argpyrimidine fractions from HPLC
System I from an AMD patient. Detection: fluorimetry at 335 nm excitation, 385
nm emission using Waters™ 474 Scanning Fluorescence Detector.
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Figure 3.9. Representative Standard Calibration Curves for CML,
pentosidine and PEC on HPLC System II. ESI MRM, electrospray ionization
mass spectrometry multiple reaction monitoring, was used for detection of
CML at 205.1 / 84.1 m/z and PEC at 227.3 / 106.1 m/z. Each standard mixture
was analyzed in triplicate on each analysis day.
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* PEC (15 pmol) was added as an internal standard to each plasma hydrolysate prior to chromatography on HPLC System I. CML and
PEC (internal standard) were quantified by LC-MS; pentosidine was quantified by LC-fluorimetry following chromatography on HPLC
System II. Protein was quantified by amino acid analysis. CML and pentosidine values were corrected based on the recovery of PEC
from HPLC System II. STD, standard deviation; RSD, relative standard deviation.

Table 3.10. Summary of Plasma Protein CML and Pentosidine Concentrations, and Overall PEC Recovery*

3.3 Elevated CML and Pentosidine in AMD Plasma
Plasma from a total of 30 control subjects and 60 AMD subjects were
analyzed for CML and pentosidine by LC-MS and LC-fluorimetry, including 30
patients with early-stage dry AMD (AMD Category 2) and 30 patients with
advanced-stage AMD (AMD Category 4). Overall, AMD patients (n = 60)
exhibited higher CML (~ 1.6x) and pentosidine (~ 1.8x) (p-values < 0.0001)
compared with the control plasma (Figure 3.10 and Table 3.11). Correlation
between CML and pentosidine concentrations shows that significantly more
donors with both CML and pentosidine elevated were apparent in AMD patients
than in the controls. Higher mean levels of CML (1.4x – 1.7x) and pentosidine
(1.6x – 1.9x) were observed in both early-stage and advanced AMD patients
relative to control plasma (p-values < 0.001) (Figure 3.11 and Table 3.11).
Comparing Category 2 to Category 4 AMD patients, CML was elevated ~ 10%
(p-value = 0.30) and pentosidine was elevated ~ 20% (p-value = 0.09) in
advanced-stage AMD patients, however these differences were not statistically
significant (Figure 3.11 and Table 3.11).
Logistic regression modeling of the CML data from all control and AMD
donors yielded a c-statistic equal to 0.80 for AMD patients (Table 3.12),
supporting a 80% likelihood that a randomly selected person with elevated CML
will be an AMD case rather than a control. Similar logistic regression modeling of
the pentosidine data yielded a c-statistic equal to 0.92 (Table 3.12), supporting a
92% likelihood that a randomly selected person with elevated pentosidine will be
an AMD case. Small difference in c-statistics for CML (0.74 - 0.85) and for
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pentosidine (0.90 - 0.94) were observed from early AMD and advanced-stage
AMD (Table 3.12) with slightly higher values obtained for advanced stage
disease. Bootstrap resampling and 10-fold cross-validation verified all c-statistics
and 95% CIs. The predicted risk of AMD was estimated by odds ratio (OR) for
donors with elevated CML and pentosidine relative to the median levels in control
plasma (Table 3.11). The large confidence intervals associated with the ORs
indicate that the OR values lack precision. Additional donor plasma must be
analyzed to improve the precision of the OR estimates.
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Figure 3.10. Carboxymethyllysine (CML) and Pentosidine are Elevated in
AMD Plasma. CML (A) and pentosidine concentrations (B) were quantified by
LC-MS and LC-fluorimetry from control (n = 30) and AMD (n = 60) plasma
donors are shown with mean (Δ) results ± standard deviation (SD) and with
median (○) results ± first and third quartiles (Q1, Q3). For all AMD patients (n
= 60), the mean concentration of CML was 42.7 ± 14.9 pmol/mg and
pentosidine was 1.65 ± 0.52 pmol/mg. P-values (two sided t-Test) were
determined from log-transformed concentrations. This data was presented in
Table 3.10 and 3.11 with odds ratios and 95% confidence intervals.
Correlation between CML and pentosidine concentrations are shown for the
control (C) and AMD (D) cohorts with horizontal and vertical dashed lines
indicating median control values. Significantly more donors with both CML and
pentosidine elevated are apparent in AMD patients than in the controls (upper
right quadrants in C and D).
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Figure 3.11. Carboxymethyllysine (CML) and Pentosidine are Elevated in AMD Plasma with Different
Categories. CML and pentosidine quantified by LC-MS and LC-fluorimetry from control (n = 30) and AMD (n =
60) plasma donors, including early-stage dry AMD Category 2 (n = 30) and advanced-stage AMD Category 4 (n =
30) are shown with mean (Δ) results ± standard deviation (SD) and with median (○) results ± first and third
quartiles (Q1, Q3). The data is presented in Table 3.10 and 3.11 by category of AMD progression with odds ratios
and 95% confidence intervals. P-values (two sided t-Test) were determined from log-transformed concentrations.
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CML and pentosidine concentrations were determined by LC-MS and LC-fluorimetry. Protein was quantified by
amino acid analysis. The odds ratio (OR) reflects the AMD risk for donors exhibiting elevated levels of either
CML or pentosidine markers relative to the median control levels (CML ≥ 24.3 pmol/mg and pentosidine ≥ 0.93
pmol/mg plasma protein, respectively). P values were determined using the Fischer Exact Test. AMD
categories are based on the AREDS classification system. Odds ratios, 95% CI and p-values are based on logtransformed CML and pentosidine concentration. The large 95% confidence internals include the estimated
ORs lack precision because of the relatively small number of samples (i.e., n = 30 or n = 60).

Table 3.11. CML and Pentosidine Markers in Control and AMD Plasma
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The C-statistic and 95% CI were determined by a logistic regression model fit with log-transformed CML and
pentosidine concentrations as independent variables, and was validated by bootstrap resampling and 10fold cross-validation.

Table 3.12. C-statistics for CML and Pentosidine

3.4 AMD Risk Based on Multiple Markers
Another oxidative protein modification identified as an AMD biomarker is
2-(ω-carboxyethyl)pyrrole (CEP). CEP modifications are generated by covalent
adduction of primary amino groups with 4-hydroxy-7-oxohept-5-enoic acid
(HOHA), an oxidation fragment derived uniquely from docosahexaenoic acid
(DHA)-containing phospholipids (Crabb et al., 2002). CEP adducts and CEP
autoantibody were quantified by competitive ELISA in the same control plasma (n
= 30) and AMD plasma (n = 56) (Table 3.13), that were analyzed for CML and
pentosidine. Higher mean levels of CEP adducts (~ 2x) were found in AMD
plasma (p-value < 0.0001) (Figure 3.12). CEP autoantibody was also elevated ~
30% compared with the normal control (p-value = 0.25) (Figure 3.12), however,
the elevation of CEP autoantibody in AMD patient was not significant, so CEP
autoantibody values were not used in the statistical analysis. Comparison of CEP
adducts, CEP autoantibody, CML and pentosidine levels in control and AMD
plasma are presented in Figure 3.12. The relative standard deviation (RSD) of
CEP adduct and CEP autoantibody values from ELISA quantification was 52.1%
and 70.0%. For the quantification of CML and pentosidine using LC-MS and LCfluorimetry, the RSD of the average values was 35.8% and 23.8%, respectively.
Notably, the chromatography assays for CML and pentosidine exhibit less
variability compared with the ELISA for CEP.
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* CEP adducts and autoantibody titer were determined by ELISA. STD, standard deviation; RSD, relative standard deviation.

Table 3.13. Summary of Plasma CEP Adducts and CEP Autoantibody Concentrations*

Figure 3.12. CEP Adducts, CEP Autoantibody, CML and Pentosidine are
Elevated in AMD Plasma. CEP adducts (pmol/ml) and CEP antoantibody titer
were quantified in plasma by ELISA in control (n = 30) and AMD patients (n =
56). CML and pentosidine were quantified by LC-MS and LC-fluorimetry from
control (n = 30) and AMD (n = 60) plasma donors. The mean (Δ) results ±
standard deviation (SD) and the median (○) ± first and third quartiles (Q1, Q3)
are shown. For AMD patients, the mean concentration of CML was 2.07 ± 0.70
nmol/ml, pentosidine was 79.5 ± 23.1 pmol/ml, CEP adduct was 44 ± 22
pmol/ml, and CEP autoantibody was 1.8 ± 1.2. P-values (two sided t-Test)
were determined from log-transformed concentrations.
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Correlation of CEP adducts, CML and pentosidine is shown in Figure 3.13.
All three oxidative protein modifications were correlated closely, with 75% to 87%
elevated above median control levels in AMD patients compared with only 23%
to 27% elevated in control donors. When considered together as markers for
AMD, pentosidine and CML yielded an OR for AMD of 21.4 (95% CI, 6.9, 65.9),
CML and CEP adducts yielded an OR for AMD of 9.9 (95% CI, 3.5, 27.9),
pentosidine and CEP adducts yielded an OR for AMD of 9.1 (95% CI, 3.3, 25.2).
Again the large 95% confidence intervals indicate these OR values lack precision
and additional plasma must be analyzed to improve precision.
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markers elevated relative to the median control values.

indicate the median control values. The predicted risk of AMD was evaluated by odds ratio calculated from two

patients (n = 56 for the analysis of CEP adducts and n = 60 for the AGEs). The horizontal and vertical dashed lines

CEP adducts and CML; (C) CEP adducts and pentosidine. Grey denotes control (n = 30) donors, red denotes AMD

Figure 3.13. Correlation Between Plasma CEP Adducts, CML and Pentosidine. (A) CML and pentosidine; (B)

Sensitivity and specificity measures were determined with receiver
operating characteristic (ROC) curves from all AMD cases and controls for CML,
pentosidine and CEP adducts alone, and for the combined markers (Table 3.14).
Calculated to maximize the sum of the two values, sensitivity was greater for
CML (83%) and pentosidine (85%) alone than for CEP (68%) alone. The
specificity of pentosidine (93%) and CEP (87%) alone were higher than that for
CML alone (73%). The p values for the comparison of c-statistics of single
markers demonstrated that there was no significant difference for CEP compared
with CML and for pentosidine compared with CEP. But there was significant
difference in the c-statistics between CML and pentosidine, which suggests that
pentosidine has a higher discrimination accuracy than CML. The combination of
CML and pentosidine improved specificity to 95% with 83% sensitivity; the
combination of CML and CEP adducts improved specificity to 93% with 71%
sensitivity; and the combination of pentosidine and CEP adducts improved
specificity to 95% with 86% sensitivity. The area under the ROC curve (c-statistic)
is a measure of the discriminating accuracy of these markers and was verified by
bootstrap resampling and by 10-fold cross-validation. Pentosidine levels
exhibited the largest c-statistics and alone could discriminate between AMD and
control plasma with 92% accuracy and with 95% accuracy in combination with
CEP adducts. The p values here indicate that c-statistics of the combined
markers and the single marker are not significantly different, except for possibly
combined CML and pentosidine versus CEP alone (p-value = 0.06).
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Sensitivity and specificity were determined from ROC curves to maximize the sum of the two values and constructed from the output of
logistic regression analysis fit with either CEP adduct, CML, or pentosidine concentrations alone, or in combination. The concentration
of CML was expressed in nmol/ml, and pentosidine and CEP adducts were expressed in pmol/ml. C-statistics, 95% CI and p values
derived from single and joint markers were determined with SAS 9.1 based on log-transformed maker concentrations. Verification of cstatistics and 95% CI was performed by bootstrap resampling and 10-fold cross-validation. The c-statistics is a measure of the area
under the ROC curve and of the accuracy of the markers to discriminate between AMD cases and controls, with 1.0 equivalent to
100% accuracy and 0.5 equal to no discrimination. Combining markers improved the c-statistics relative to the markers alone.

Table 3.14. Sensitivity and Specificity of CML, Pentosidine and CEP Adducts

3.5 The Influence of Age on Plasma CML and Pentosidine Levels
Study population characteristics are summarized in Table 3.15, including
age, gender, race, smoking status and health history. Comparison of plasma
AGE levels by donor age (Figure 3.14) revealed that CML concentrations are
increased gradually with age in both control and AMD donors (Figure 3.14A), and
AMD patients exhibit significantly higher mean levels of CML than controls at all
ages (Figure 3.14B). Mean pentosidine remained stable with age in controls, but
increased gradually with age in AMD donors (Figure 3.14C) and was higher than
in controls at all age (Figure 3.14D).
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Table 3.15. Characteristics of Study Population
Control

AMD
Category 2

AMD
Category 4

n=30

n=30

n=30

Mean ± SD

72 ± 5

74 ± 10

73 ± 5

Range

64 - 80

56 - 91

64 - 89

Male

15 (50.0%)

15 (50.0%)

15 (50.0%)

Female

15 (50.0%)

15 (50.0%)

15 (50.0%)

Caucasian

30 (100%)

30 (100%)

30 (100%)

28 (93.3%)

24 (80.0%)

29 (96.7%)

2 (6.7%)

6 (20.0%)

1 (3.3%)

Hypertension

21 (70.0%)

15 (50.0%)

19 (63.3%)

Hyperlipidemia

15 (50.0%)

15 (50.0%)

9 (30.0%)

Diabetes

0 (0.0%)

3 (10.0%)

2 (6.7%)

Cardiovascular disease

6 (20.0%)

8 (26.7%)

4 (13.3%)

Property

Category

Age (year)

Gender

Race
Smoking Status
Non-smoker
Smoker

Health History
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Figure 3.14. CML and Pentosidine Plasma Levels by Donor Age. (A) CML
and (C) pentosidine levels in the control (grey) and AMD (red) study
populations are shown plotted by donor age. Pearson’s correlation analysis
(horizontal color coded lines and p-value from log-transformed data) revealed
gradual increases in CML with age. Pentosidine in AMD donors also gradually
increased with age, while in control donors the level of pentosidine was stable
with age. (B) CML and (D) pentosidine levels in control and AMD donors are
plotted by age group, including 51-60 y (AMD n = 4), 61-70 y (control n = 12,
AMD n = 18), 71-81 y (control n = 18, AMD n = 28), ≥ 81 y (AMD n = 10). Fold
difference in CML and pentosidine concentrations is indicated between the
control and AMD groups. Asterisks reflect p-values from a two sample t-test
(*** p < 0.001, ** p < 0.01, * p < 0.05).
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3.6 The Influence of Gender and Health Factors on Plasma CML and
Pentosidine
Plasma CML and pentosidine concentrations were compared by gender
and health history, including smoking, hypertension, hyperlipidemia, diabetes and
cardiovascular disease (Figure 3.15). For each comparison, significant
differences in CML and pentosidine concentrations were observed between AMD
and control donors. No statistically significant differences in CML concentrations
were detected within the AMD or control cohorts. Small but significant differences
were detected in pentosidine levels within the AMD cohorts. Specifically, in AMD
patients, mean pentosidine levels were higher in donors with hypertension and
cardiovascular disease. Notably, these comparisons provide preliminary results
because of the relatively low number of donors analyzed.
From the data shown in Table 3.9 and Figure 3.4, 3 control (C-1, C-10, C18) and 2 AMD samples (A2-10, A4-7) may be considered as suspect diabetics
based on furosine concentrations greater than the diabetic mean – 1 SD (≥ 1.19
pmol/mg). However, the medical records for these patients provided no
indications that any were diabetics. Notably none of these patients exhibited
furosine concentrations greater than the control mean + 2 SD (≥ 1.25 pmol/mg).
The quantification of furosine confirmed that there were no unknown diabetes in
our study group.
Both CML and pentosidine have been reported to increase in diabetes
(Goh et al., 2008). In our study group, CML and pentosidine concentrations in the
five patients that were both AMD and diabetic (A2-5, A2-16, A2-23, A4-13, A4-17)
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were less than 1 SD from mean concentrations (Table 3.10), except for A2-16
which exhibited very high pentosidine but somewhat reduced CML. The three
control suspect diabetics (C-1, C-10, C-18) showed no significant difference in
CML and pentosidine concentrations compared with the mean of other normal
controls. The two AMD suspect diabetics (A2-10, A4-7) also have CML and
pentosidine concentrations within 1 SD of the AMD mean concentrations (Table
3.10). Notably, AMD patient A4-28 exhibited the highest CML and pentosidine
concentrations but showed a furosine concentration that was not elevated (Table
3.9). These data demonstrate that the elevated levels of CML and pentosidine in
plasma were associated with AMD pathology and not diabetes.
CEP adduct concentrations in the four diabetic AMD patients (A2-16, A223, A4-13, A4-17) were less than 1 SD from the mean concentrations (Table
3.13). CEP adduct levels in the control and AMD suspect diabetics showed no
significant difference compared with group mean concentrations (Table 3.13).
Notably, AMD patient A4-8 exhibited the highest CEP adducts concentration but
showed a furosine concentration within 1 SD from the mean concentration (Table
3.9). The results showed that the elevated levels of CEP adducts in plasma were
associated with AMD but not diabetes, which is consistent with results from the
previous studies (Gu et al., 2009).
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Figure 3.15. AGE Maker Concentrations Stratified by Demographic and Health Factors. Plasma protein CML
and pentosidine levels in the AMD and control study populations are plotted based on donor status with regard to
gender, status of smoking, hypertension, hyperlipidemia, diabetes and cardiovascular diseases. Sample size per
group is indicated and asterisks reflect p-values from a two sample t-test of log-transformed marker concentrations
(*** p < 0.001, ** p < 0.01, * p < 0.05). F, female, M, male; S, smokers; NS, non-smoking; W, with; W/O, without.

CHAPTER IV
DISCUSSION AND CONCLUSIONS

4.1 Discussion
Extracellular and intracellular proteins can be modified by non-enzymatic,
oxidative glycosylation to form advanced glycation end-products (AGEs) (Maillard
et al., 1912; Glomb et al., 2001). Significant targets of glycation modifications are
collagens, which are major components of extracellular matrices, such as
Bruch’s membrane (Johnson et al., 2004). Previous immunohistochemical
studies have demonstrated the existence of AGEs in Bruch’s membrane, drusen
and retinal pigment epithelium (RPE) (Ishibashi et al., 1998; Handa et al., 1999;
Crabb et al., 2002; Glenn et al., 2009). The high light exposure and high oxygen
tension in the retina provide a permissive environment for oxidation, including
oxidative glycation of intracellular proteins in the RPE and extracellular proteins
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in the adjacent Bruch’s membrane (Sarks et al., 1999; Crabb et al., 2002). With
the choriocapillaris adjacent to Bruch’s membrane and with the RPE serving as a
blood-retinal barrier, AGEs formed in the RPE and Bruch’s membrane may also
find their way into the blood stream. The accumulation of oxidative modifications
in Bruch’s membrane and drusen have been proposed to be catalyst of AMD
pathology (Crabb et al., 2002; Gu et al., 2003; Ebrahem et al., 2006; Gu et al.,
2009).
AGEs exacerbate disease progression through two general mechanisms:
modifying molecules and forming nondegradable, cross-linked aggregates, thus
impairing normal tissue functions, and altering cellular function directly through
receptor-mediated activation (Howes et al., 2004). Cross-linking of long-lived
extracellular matrix proteins in Bruch’s membrane and the inability of RPE cells
to degrade AGE intracellularly contributes to impaired cellular physiology. It is
important to note that AGEs, in addition to their established role in damaging
protein function, could act as important instigators of retinal disease by provoking
pro-inflammatory cascades that are modulated by key receptors expressed by
retinal cells. In the context of the outer retina, studies have established that the
receptor for AGEs (RAGE) is expressed on RPE cells and that receptor levels
are significantly increased in AMD, especially on cells adjacent to drusen
(Yamada et al., 2006). RAGE can be upregulated with aging and disease, and
induces a pathologic response through several signal transduction pathways
(Schmidt et al., 2001). RAGE forms a complex on the plasma membrane, which
is thought to endocytose AGE-modified proteins as a protective response
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(Vlassara et al., 1995). The RAGE complex on plasma membrane can regulate
the diffusion of AGEs between RPE cells and the choriocapillaris. We
hypothesize that the plasma concentrations of AGEs in AMD may reflect the
accumulation of AGEs in RPE and Bruch’s membrane, and therefore be useful
for accessing AMD susceptibility.
Advanced glycation end-products accumulate during aging, especially in
choriocapillaris and Bruch’s membrane (Handa et al., 1999), and are highly
expressed in CNV membrane (Ishibashi et al., 1998). Several studies have
shown that AGEs stimulate the proliferation of choroidal endothelial cells, the
expression of matrix metalloproteinase type 2, the upregulation of growth factors
such as VEGF, and angiogenesis in vivo (Hoffmann et al., 2002). Accordingly,
they may be important promoters of CNV in exudative AMD.
We quantified the plasma protein concentrations of two advanced glycation
end-products, namely CML and pentosidine, both of which are chemical
modifications of protein lysine. The results from this study showed that mean
levels of CML and pentosidine were significantly elevated in AMD plasma. To be
exact, the mean CML concentration was ~ 60% higher in AMD patients (p <
0.0001) than in healthy control patients. Similarly, the mean pentosidine level in
AMD patients was found to be elevated ~ 80% relative to the control donors (p <
0.0001). In our study group, AMD patients exhibited either early-stage dry AMD
(AMD Category 2) (n = 30) or advanced-stage AMD (AMD Category 4) (n = 30).
These preliminary results showed no significant differences in plasma
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concentrations of CML and pentosidine between patients from AMD categories 2
and 4.
Statistical analyses were pursued to evaluate the effectiveness of plasma
protein CML and pentosidine as AMD biomarker. The estimated odds ratios for
CML (9) and pentosidine (11) suggest high potential for evaluating AMD risk,
however, the large 95% confidence intervals surrounding these estimates
indicate that the values lack precision and more studies are needed to refine this
statistic. C-statistics were used to evaluate the likelihood that a randomly
selected person will be an AMD case rather than a control based on elevated
plasma protein CML or pentosidine. As single markers, pentosidine concentration
provided ~ 92% discrimination accuracy, and CML provided ~ 80% accuracy.
This suggests that pentosidine will be the more powerful and efficient in
predicting AMD susceptibility.
The effectiveness of CML and pentosidine biomarkers to predict AMD
susceptibility was compared with that of CEP adducts, an oxidative modification
generated uniquely from DHA phospholipids and elevated in AMD plasma (Gu et
al., 2009). Elevated CEP adducts in our study population provided ~ 81%
accuracy in predicting AMD alone, very similar to that of CML (~ 80% accuracy).
Using CEP-adducts and CML together provided ~ 89% accuracy, while CEPadducts and pentosidine together provided ~ 95% accuracy in discriminating
AMD patients from normal controls.
Both CML and pentosidine exhibit significantly higher mean levels in AMD
than controls at all ages analyzed. The demographic results showed that
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elevated CML was correlated with age in both controls and AMD donors.
However, elevated pentosidine was only correlated with age in AMD donors, and
remains relatively stable with age in control donors. This is consistent with
previous reports of age-dependent increases in AGEs accumulation, and
suggests that AGEs may play important roles in age-related pathologies (Sell et
al., 1990; Brownlee et al., 1995). For example, AGEs likely contribute to the agerelated structural and physiological changes in Bruch’s membrane, including an
increase in overall thickness (Okubo et al., 1999; Zarbin et al., 2004; Glenn et al.,
2009).
Previous studies have shown that diabetes may induce elevated plasma
CML and pentosidine. For example, in diabetic patients plasma CML
concentrations have been reported to be 1.92 nmol/ml (Misselwitz et al. 2002),
2.20 nmol/ml (A Ahmed et al., 2007) by ELISA and 2.90 nmol/ml (Lieuw et al.,
2004) by LC/MS/MS. Our results showed the mean plasma CML concentration to
be ~ 1.4 nmol/ml (27.6 pmol/mg) for normal controls, and ~ 2.1 nmol/ml (42.7
pmol/mg) for AMD patients. For the five diabetic AMD patients, the mean CML
concentration was ~ 1.5 nmol/ml (32.7 pmol/mg) (Table 4.1). Plasma pentosidine
concentrations in diabetic patients have been reported to be 90.2 pmol/ml
(Yamamoto et al., 2008) and 169.7 pmol/ml (Yoshida et al., 2005) by ELISA and
5.0 pmol/mg by HPLC (Odetti et al., 1992). Our results showed the mean plasma
pentosidine concentration to be ~ 46.8 pmol/ml (0.95 pmol/mg) for normal
controls, and ~ 79.5 pmol/ml (1.65 pmol/mg) for AMD patients. For the five
diabetic AMD patients, the mean pentosidine concentration was ~ 81.6 pmol/ml
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(1.7 pmol/mg) (Table 4.1). Our results suggest that diabetes had no inflationary
impact on the CML concentration in AMD patients, and the minimal positive
impact on the pentosidine concentration was not statistically significant (p-value ~
0.8, two sided t-Test).
Table 4.1. Comparison of CML and Pentosidine from Diabetic and
Nondiabetic AMD and Control Plasma Donors

n

CML

Pentosidine

Mean ± SD

Mean ± SD

nmol/ml

pmol/mg

pmol/ml

pmol/mg

Control
Nondiabetics

30

1.37 ± 0.53 27.6 ± 10.1

46.8 ± 7.0

0.95 ± 0.15

AMD
Nondiabetics

55

2.11 ± 0.70 43.6 ± 14.9

79.3 ± 23.1

1.64 ± 0.52

AMD
Diabetics

5

1.54 ± 0.49 32.7 ± 11.2

81.6 ± 25.4

1.73 ± 0.61

CML and pentosidine quantified by LC-MS and LC-fluorimetry from control (n
= 30) and AMD (n = 60) plasma donors, including non-diabetes (n = 55) and
diabetes (n = 5) are shown with mean results ± standard deviation (SD).

Because diabetes mellitus is a very prevalent disease affecting ~ 200
million people worldwide, including 20 million in the USA (Mohamed et al., 2007),
it was important to determined if the observed elevation of CML and pentosidine
in AMD patients was due to undiagnosed diabetes. To address this issue we
measured plasma protein furosine because furosine has been used elsewhere to
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predict the progression of diabetic complications (Monnier et al., 2005). The
results showed that in our study group AMD patients without diabetes exhibited
the same mean furosine concentration as normal controls. Notably the five AMD
patients with diabetes exhibited ~ 20% higher furosine concentration compared
with the normal controls. The furosine results suggest that there were no
unknown diabetic patients in our study population. Accordingly, the CML and
pentosidine plasma levels in AMD patients appear elevated because of AMD
pathology rather than diabetes.
Previous studies have also shown that CML and pentosidine accumulate in
kidney disorders. For example, in hemodialysis patients, plasma concentrations
of CML have been reported to be 8.32 nmol/ml (Busch et al., 2004) and 121.4
pmol/mg (Wagner et al., 2006) by ELISA, and in end-stage renal disease patients
to be 4.52 nmol/ml by ELISA (Misselwitz et al., 2002). Patients with kidney
disorders appear to exhibit 2-3 times higher plasma CML concentrations than
AMD patients. In hemodialysis patients, plasma concentrations of pentosidine
have been reported to be 1.58 nmol/ml (Busch et al., 2004) and 15.0 - 25.4
pmol/mg (Jadoul et al., 1999) by HPLC, and in uremic, non-diabetic subjects to
be 23.7 - 24.7 pmol/mg by HPLC (Odetti et al., 1992; Odetti et al., 1995).
Patients with kidney disorders appear to exhibit 14 - 20 times higher plasma
pentosidine concentrations than AMD patients. With regard to AGEs plasma
levels, kidney disorders and AMD are easily differentiated based on the relatively
large difference in CML and pentosidine concentrations.
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Patients with rheumatoid arthritis have also been reported to have plasma
pentosidine concentrations of 152 pmol/ml (Chen et al., 1999) and 155 pmol/ml
(Senolt et al., 2007) by HPLC, which is about 2 times higher than plasma
pentosidine concentrations in AMD. Although plasma levels of CML and
pentosidine are elevated in diseases other than AMD, the different scales of
elevation, the different clinical symptoms of the diseases, and the availability of
quantitative furosine assays will allow CML and pentosidine to be useful for
monitoring AMD susceptibility.

4.2 Conclusions
Taken together, this study supports the potential utility of plasma proteinbound CML and pentosidine as biomarkers for predicting AMD susceptibility,
particularly in combination with CEP biomarkers. The statistical analyses suggest
that in combination, these biomarkers can discriminate between AMD and control
donors with up to ~ 95% accuracy. Further optimization of the assay could
decrease analysis time and improve efficiency.
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